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CHAPTER 1  
Introduction 
1.1 Epigenetic and nucleosome structure 
DNA is the blueprint of life that holds the information required for proper functioning of 
all living organisms. Roughly 2 m of DNA with a total of 3 billion base pairs are packaged into a 
nucleus of roughly 10 µM diameter in the form of nucleosomes. The nucleosome is the structural 
unit of chromatin, which comprise DNA and hydrophilic, basic nuclear histone proteins. 
Roughly 146 base pairs of DNA is coiled around two copies each of four canonical histone 
proteins (H2A, H2B, H3, and H4) in a single unit of nucleosome.  inker histones H  connect the 
nucleosome with an additional   -6   p of D A to form chromatin fi ers of   1 nM in diameter. 
Chromatin fibers are further condensed to give thread like structures called chromosomes (Figure 
1.1).
1
  
 Epigenetic mechanisms are inheritable factors that alter gene expression without 
alteration of the DNA sequence. DNA methylation (Figure 1.1, Part 1), post translational 
modifications on the histone tails (Figure 1.1, Part 2), chromatin remodeling, and  non-coding 
RNA (Figure 1.1, Part 3) represent epigenetic mechanisms that play important roles in 
transcription, DNA repair and replication.
2
  
 
 
2 
 
 
 
Figure 1.1: Epigenetic mechanisms.
3
 Double stranded DNA is wrapped around histones to 
form nucleosomes. Nucleosomes are joined together by linker histone and DNA into chromatin 
fibers, which further condense to generate highly ordered chromosome. Reproduced with 
permission from Elsevier, Mutation research, 727 (2011), 62-71. 
 
Histones proteins contain structured globular domain that lies within the nucleosome core 
and flexible N-terminal tails that protrude out of the nucleosome. These highly basic flexible 
tails act as substrates for various enzymes to undergo an enormous number of post translational 
modifications, including acetylation and methylation of lysines and arginines, phosphorylation of 
serines and threonines, ubiquitinylation and sumolyation of lysines, and ribosylation (Figure 
1.2).
4
 These dynamic post translational modifications regulate cellular processes like 
transcription, DNA repair and replication, which store the epigenetic memory in the form of a 
histone code.  Depending on the modifications on histones, chromatin is present in two distinct 
3 
 
 
dynamic structural states: heterochromatin (closed chromatin, gene repression) and euchromatin 
(open form of chromatin, gene activation). For example, H4K8 acetylation, H3K14 acetylation, 
H3S10 phosphorylation, and trimethylation of H3K36, H3K79 lead to active chromatin, whereas 
trimethylation of H3K9 and H3K27 lead to heterochromatin state.
5
 Given the focus of the thesis 
on histone deacetylase proteins, histone acetylation will be further explained in the following 
sections.  
 
 
 
 
 
 
Figure 1.2: Post translational modification of the histone proteins.
4
 Modification on amino 
acids of the core and N-terminus histones is represented as colored shapes. Methylation (green 
pentagons), phosphorylation (yellow circles), acetylation (red triangles), and ubiquitinylation 
(blue stars).  Reproduced with permission from Elsevier,Current Biology 14 (2004), 546-551. 
 
1.2 Histone acetylation and deacetylation 
 Histone acetylation is a dynamic posttranslational modification that plays an important 
role in the regulation of gene expression.
6
 Two classes of enzymes regulate the acetylation state 
of histones: histone acetyl transferase (HAT) and histone deacetylase proteins (HDAC) (Figure 
1.3). Histone acetyl transferase proteins catalyze the transfer of an acetyl group from acetyl-
coenzyme A to the ε-amino group of lysines and neutralize the positive charge of the lysine 
4 
 
 
residue. Neutral acetylated lysine residues prevent electrostatic interaction with the negatively 
charged DNA, leading to chromatin relaxation (euchromatin) and activation of gene expression. 
On the other hand, deacetylation of acetylated lysine catalyzed by histone deacetylase restores 
the positive charge of the lysine residues on the histones. The cationic lysine tails strongly 
interacts with the phosphate backbone of DNA promoting the closed chromatin structure 
(heterochromatin), which is responsible for gene inactivation. Overall, a dynamic interplay 
between the two enzymatic reactions plays a crucial role in regulation of transcription of gene.
7
  
 
 
 
Figure 1.3: Acetylation and deacetylation of lysine residues on histones. 
 
1.3 Histone deacetylase proteins in human 
Removal of acetyl groups from acetylated lysine residues on the histone amino termini is 
catalyzed by histone deacetylases (HDAC) proteins, which are highly conserved from yeast to 
humans.
8
 In humans, eighteen HDAC proteins are known and divided into four classes based on 
their catalytic mechanism, size, cellular localization, number of catalytic active sites, and 
homology to yeast HDAC proteins (Figure 1.4). Class I, II, and IV are zinc-dependent 
deacetylases, whereas Class III contains the seven sirtuin (silent information regulator) proteins 
which require NAD
+
 for histone deacetylation
9 
similar to yeast Sir proteins (silent information 
regulator). Because of a different catalytic mechanism, distinct from the other classes, sirtuins 
will not be discussed further in this dissertation.  
5 
 
 
Class I HDACs are 40-55kDa predominately nuclear proteins ubiquitously expressed in 
all human cell lines and tissues and important in regulation of cell proliferation and repression. 
Class I HDACs include HDAC1, HDAC2, HDAC3, and HDAC8, which have high sequence 
similarity in the catalytic site with yeast Rpd3.
10-12
 Among them, HDAC1 and HDAC2 are 
highly related proteins with 85% amino acid sequence identity. Except HDAC8, class I HDACs 
are components of multi-protein transcriptional repressor complexes.
13,14
 For example, HDAC1 
and HDAC2 are found in the Sin3
15
, NuRD (nucleosome remodeling and deacetylating),
16,17
 and 
Co-REST (co-repressor for element-1 silencing transcription factor)
18
 complexes, whereas 
HDAC3 is part of NCoR complex.
19,20
 
 Class II HDAC proteins are homologous to yeast Hda1,
21-23
 
 
exhibit tissue specific 
expression, and can shuttle between the cytoplasm or nucleus in response to metabolic signal. 
The concentration in the cytoplasm suggests non-histone proteins are likely substrates. Class II 
HDACs are 80-131 kDa in size and include HDAC4, HDAC5, HDAC6 HDAC7, HDAC9, and 
HDAC10. Among the three classes of HDACs, HDAC6 is a unique enzyme with two catalytic 
domains. The stronger deacetylase activity of HDAC6 resides in the C-terminal second catalytic 
domain.
24,25
 Finally, class IV deacetylases includes a sole protein HDAC11,
26
 which is 39 kDa in 
size and shares sequence similarity with the catalytic core of class I and II HDAC proteins.  
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 : Schematic representation of zinc-dependent histone deacetylases
27
. Size, 
domain composition, and localization of Class I, II, and IV HDACs are represented. Purple 
depicts the catalytic domain and nuclear targeting sequence is shown in yellow. Reproduced with 
permission from Mol Onc, 6 (2012), 637-656. 
 
 
 
 
 
7 
 
 
1.4 Crystal structure of HDAC with acetyl-lysine mimic 
 To date, crystal structures for HDAC1, HDAC2, HDAC3, HDAC4, HDAC7, and 
HDAC8 have been reported.
13,28-32
 Until recent publication of these crystal structures, the most 
widely used model to study the structure of class I HDACs was the crystal strcuture of a histone 
deacetylase-like protein (HDLP) from a thermophilum bacterium Aquifex aeolicus, with 35.2% 
sequence homology with HDAC1 isoform.
33
 The amino acids present in the catalytic active site 
of HDLP structure and class I HDACs are similar and highly conserved, hence HDLP crystal 
structure was widely used for elucidation of the catalytic mechanism of deacetylases (Section 1.5 
and Figure 1.6).
33
  Recently the crystallographic structure of HDAC2 resolved at 1.85Å in 
complex with SAHA, an FDA-approved HDAC inhibitor for treatment of cutaneous T-cell 
lymphoma, was reported (Figure 1.5).
28
 The overall protein conformation of HDAC2 is similar 
to the previously solved HDLP structure, however at higher resolution. SAHA, an acetyl-lysine 
(HDAC substrate) mimic chelates the active site Zn
+2
 in trigonal bipyramidal fashion. The alkyl 
linker chain of SAHA interacts with the hydrophobic, 11Å channel. The phenyl capping group of 
SAHA located towards the solvent-exposed region is shown to interact with amino acid residues 
at the opening of the HDAC binding pocket. In addition, a 14Å internal cavity present at the 
bottom of the active site serves as an acetate escape channel (Figure 1.5A).  
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Figure 1.5: Crystal structure of HDAC2 in complex with SAHA.
28
  A. The metal binding 
moiety of SAHA interacts with zinc (cyan sphere) at the bottom of the active site. Capping group 
is outside the active site pocket. The hydrophobic linker accommodates the 11Å channel and 
connects the two regions of SAHA. B. Cut way view of the binding pocket of HDAC2 complex 
with SAHA. SAHA is represented in pink stick models, zinc is indicated in a cyan sphere, and 
the key active site residues are shown as grey sticks. Binding interactions of hydroxylamine, zinc 
and active site residues are shown in solid red line. Reproduced with permission from J. Biol. 
Chem, 288 (2013), 26926-26943. 
  
     To study the class II deacetylase enzymes, crystal structures of bacterial FB188 HDAH 
(histone deacetylase-like aminohyolase from Bordetellal Alcaligenes strain FB188) is widely 
used
34
. Bacterial FB188 HDAH is quite distinct from HDLP structure with only 20% sequence 
identity, whereas show high sequence and functional similarity to class IIb HDAC6 with 30% 
and 35% identity for first and second catalytic domain respectively. In addition to HDAH, crystal 
structures of class IIa HDAC4 and HDAC7 gave insights into the active sites of class II 
deacetylases.
30,31
 The significant structural differences between class I and class II HDACs is 
observed in the regions surrounding the entrance of the active site of class II deacetylase
31
. A 
variety of class II selective HDAC inhibitors in particular HDAC6-selective were designed by 
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exploiting this region around the active site entrance,
35
 which is further highlighted in the 
docking studies of small molecule HDAC inhibitor (See section 3.2.2 of chapter 3). 
1.5 HDAC catalytic mechanism 
 A pausible catalytic mechanism for lysine deacetylation of class I, II and IV HDACs was 
postulated based on the HDLP crystallagraphic structure resolved at 1.8Å (Figure 1.6).
33
 The 
zinc ion of the active site coordinates with the carbonyl oxygen of acetyl-lysine, thereby 
polarizing and increasing the electrophilicity of the carbonyl carbon of acetyl-lysine (Figure 
1.6A). In addition, the zinc ion coordinates a water molecule to increase its nucelophilicity and 
lower the pKa (Figure 1.6A). The nucleophilicity of water is further increased by the buried Asp-
His-charge-relay system (His132/Asp173 in HDLP). Nucelophilic attack of water on the 
carbonyl carbon of acetyl-lysine generates a tetrahedral hemiketal intermediate (Figure 1.6B). 
The oxyanion of the resulting hemiketal is stabilized through hydrogen bond with hydroxyl 
group of Y297 (Y3 3 in HDAC ). Finally the active site is restored with protonation of the ε-
nitrogen of lysine by H141 (H132 in HDAC1), followed by the release of acetate (Figure 1.6C). 
Site-directed mutagenesis studies have confirmed the role of individual amino acids in the 
catalysis of lysine deacetylation.
36,37
 The active site residues among metal-dependent HDACs are 
highly conserved however, tyrosine residue (Y297) is replaced with histidine in class IIa 
HDACs, HDAC4, HDAC5, and HDAC7, which significantly decreased the deacetylation 
efficiency.
38
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Figure 1.6: Mechanism of N-acetyl lysine deacetylation by histone deacetylase proteins.
33
 
HDLP-active site residues and the homologous HDAC1 amino acid resdiues (in parenthesis) are 
labelled. Reproduced with permission from Nature, 401 (1999), 188-193. 
 
1.6 Genetic characterization of HDACs in carcinogenesis 
 Deregulation of DNA methylation and posttranslational histone modifications are the 
hallmarks of human cancer.
2,39
 HDACs role in cancer development involves more than one 
mechanism, with most studies focusing on the aberrant recruitment of HDACs to specific 
promoters of the transcription machinery resulting in unregulated gene expression.
40,41
 The 
expression pattern of HDACs is not directly related to changes in gene expression, but several 
studies have shown the presence of altered expression of individual HDACs in tumors.
42
 For 
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example, elevated expression of class I, HDAC1, HDAC2, and HDAC3 was observed in gastric 
cancer, and colorectal cancer, urothelial carcinoma, and prostate cancer.
43-46
 In colorectal cancer, 
increased expression of HDAC2 was found with loss of APC (Adenomatosis polyposis coli) 
tumor suppressor function.
47
 Up regulation of class I HDAC1, HDAC2, and HDAC3 was 
associated with enhanced tumor proliferation and tumor dedifferentiation in prostate carcinoma, 
with HDAC2 acting as an independent prognostic marker.
46
 HDAC1, HDAC2, and HDAC3 
were significantly expressed in hepatocellular carcinoma over non-cancerous lung cells, and high 
HDAC2 levels decreased the survival rate.
48,49
 HDAC8 is the only HDAC isoform overexpressed 
in pediatric neuroblastoma and is associated with poor prognosis and survival rate.
50
   
 Class II HDAC6 is significantly overexpressed in oral squamous cell carcinoma and ER 
(estrogen receptor) positive breast cancer, primary acute myeloid.
51-53
 Overexpression of 
HDAC6 augmented the motility of pancreatic cancer cells by interacting with cytoplasmic linker 
protein 170 (CLIP-170).
54
 HDAC6 regulates epidermal growth factor (EGF)-induced nuclear 
localization of β-catenin, along with activation of c-myc in various cancer cells.55 Unlike the 
other HDAC proteins, fewer studies are focused on HDAC5, HDAC7, HDAC9, and HDAC10 
with HDAC5 and HDAC7 displaying high expression in colorectal cancer.
56
 Overall, the 
expression levels of HDACs in various cancers have suggested that the HDAC-mediated 
transcription repression of tumor suppressor genes is a common phenomenon in tumor onset and 
progression. p21 is a cyclin-dependent kinase inhibitor of cell-cycle progression, which is 
hypoacetylated in variety of the tumors due to overexpression of HDACs. Inhibition of HDACs 
has shown to increase the acetylated p21 levels and gene expression, which ultimately lead to 
cell-cycle arrest of the tumor cells.
57-59
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 Overexpression of HDAC isoforms was observed in variety of cancers, and various 
studies were performed to elucidate the biological function of individual HDACs in cancer 
formation. Genetic studies were used extensively to elucidate the role of individual HDAC 
isoforms, which would greatly benefit the anti-cancer therapeutics. Several genetic studies have 
been performed so far using gene knockout and RNAi techniques. Specific deletion of HDAC1, 
HDAC2, HDAC3, and HDAC7 in mouse model lead to severe embryonic lethality due impaired 
cell cycle and loss of blood vessel formation.
60-62
 HDAC1 and HDAC2 share roughly 86% 
protein sequence identity, but HDAC2 could not compensate the loss of HDAC1 in mouse 
fibroblasts. Knockdown of HDAC3 provided the evidence that N-CoR/HDAC3 co-repressor 
complex is the key factor of the aberrant transcription regulation in PML-RARα-expressing 
acute promyelocytic leukemia cells.
63
 HDAC2 and HDAC1 knockout with siRNA resulted in the 
suppression of the growth of colon cancer cells and sensitization for TRIAL-induced 
apoptosis.
44,64
 Cells depleted of both HDAC1 and HDAC2 are intolerant to DNA-damaging 
agents. HDAC1 and HDAC2 are responsible for deacetylation of H3K56Ac, and cells depleted 
of both the isoforms lead to sensitization to the DNA-damaging agents, demonstrating a role in 
DNA damage response.
65
 In Hep3B cells, inactivation of HDAC1 through specific siRNA 
resulted in regression of tumor cell growth and induced caspase-independent autophagic cell 
death.
66
 In osteosarcoma and breast cancer cells, knockdown of HDAC1 resulted in cell cycle 
arrest, growth inhibition and increase of apoptosis
67
 whereas, knockdown of HDAC2 in breast 
cancer cells negatively regulates p53 DNA binding activity, inhibits cell proliferation, and 
induces cell senescence
68
.  
 
13 
 
 
 HDAC4, a class II isoform is a key regulator in chondrocyte hypertrophy and 
skeletogenesis, as revealed from knockout studies.
69
 HDAC4 plays an important role in the 
regulation of acetylation levels, stability, and functional activity of HIF- α (Hypoxia-inducible 
factor 1), which is vital to the development of cell.
70,71
 In addition, silencing of HDAC4 lead to 
high expression of p21
WAF1/CIP1
 in various human cancer cell lines, which leads to decreased cell 
proliferation and tumor growth.
57,58
 Knockdown of HDAC7 blocked cell-cycle progression 
through suppression of c-Myc expression and induced p21 and p27 protein expression levels.
59
 
Silencing of HDAC9 in endothelial cells increase the expression of microRNA miR-17-92, 
which is known for its antiangiogenic activity.
72
 In contrast, HDAC10 was identified as the key 
suppressor of MMP2 and -9 expression in cervical cancer by interacting with the promoter
73
 and 
depletion of HDAC9 and HDAC10 specifically inhibited the homologous recombination.
74
 
Specific depletion of HDAC5 with RNAi lead to defects in pericentric heterochromatin, which 
consequently resulted in cell-cycle blocking, inhibition of cell proliferation, induction of 
apoptosis, and reduction of tumor growth in vivo.
75
 Mice lacking HDAC5 and HDAC9 revealed 
the central role of class II HDACs in the regulation of cardiac stress signals and cardiac 
development.  
Mice lacking HDAC6 are the only HDAC mutant mice that are viable without a change 
in phenotype, except for elevated tubulin acetylation.
76
 In mouse embryo fibroblasts, lack of 
HDAC6 resulted in impaired function due to high levels of Hsp90 acetylation.
76
 HDAC6 is 
identified as a key component of the stress granule response. Deletion of HDAC6 in mouse 
embryo fibroblasts did not recover from oxidative stress.
77
  In K562 leukemic cells, targeted 
inhibition of HDAC6 increased the acetylation of HSP90 with disruption of chaperone function, 
leading to inhibition of pro-growth and pro survival of client proteins, such as Bcr-Abl 
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oncoprotein.
78
 While the genetic studies are very insightful in characterization of the distinct 
HDACs in cancer formation, a few serious drawbacks have limited its application. The 
experiments with small interfering RNA requires longer incubation times, which results in 
functional compensation by other HDAC family members.  Hence, HDAC inhibitors specific to 
individual HDAC isoforms would be powerful tools to study the contributions of individual 
HDAC isoforms in carcinogenesis.  
1.7 HDAC inhibitors 
 As discussed in previous section (Section 1.6), knockdown of HDACs result in the 
expression of tumor suppressor genes, cell cycle arrest, and reduction of proliferation in tumor 
cells. Hence, a variety of natural and synthetic compounds have been developed that inhibit 
HDAC proteins. In addition, the available HDAC inhibitors preferentially reduce the growth of 
tumor cells at a concentration where normal cells are resistant, making them effective anti-cancer 
drugs.
79
 Among the current HDAC inhibitors in clinic, SAHA (Vorinostat, Zolinza
TM
) and FK-
228 (Romidepsin, Depsipeptide) are FDA approved for the treatment of cutaneous T-cell 
lymphoma.
80
 In general, HDAC inhibitors possess a stereotypical three-part structure, with a zinc 
binding group docked into the active site that interacts with the catalytic zinc, a capping group 
which interacts with the amino acids near the entrance of the active site and a linker that spans 
the 11Å active site channel (Figure 1.5 and Figure 1.7).
33
  
 The three-part HDAC inhibitor pharmacophore structure is represented  in five chemical 
classes: hydroxamic acids, carboxylic acids, benzamides, electrophilic ketones, and cyclic 
peptides. Hydroxamates are extensively studied HDAC inhibitors that utilize a strong metal 
chelator a hydroxamic acid, to bind the catalytic zinc. SAHA (Suberoyl anilide hydroxamic 
acid), TSA (trichostatin), LBH-589 (panobinostat), tubastatin, tubacin, and PXD-101 (belinostat) 
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are some of the hydroxamate containing HDAC inhibitors.
81
 Among them, belinostat and 
pabinostat are currently in clinical trials.
82,83
 Benzamides utilize a amino anilide pharmacophore 
to interact with the catalytic zinc, which include entinostat (MS-275) that is currently in clinical 
trials for treatment of solid and hematological tumors.
84
 Romidepsin is a bicyclic depsipeptide 
antibiotic extracted from Chromobacterium violaceum with anti-cancer properties, approved for 
treatment of cutaneous T-cell lymphoma in patients, and in clinical trials for treatment of solid 
and hematological cancers.
85
 Romidepsin is a prodrug which undergoes reductive cleavage of the 
disulfide bond inside the human cells to release an activated thiol metabolite to chelate the zinc 
ion of the HDAC isoforms. Finally, short chain fatty acids include valproic acid and sodium 
butyrate have IC50 in millimolar range, with valproic acid showing promising results in 
combination treatment of variety of cancers.
86,87
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Figure 1.7: Chemical representation of HDAC inhibitors. The pharmacophore structure of 
HDAC inhibitor is divided into three regions: metal binding moiety, capping group and a linker 
that connects the two regions. Select HDAC inhibitors discussed in this dissertation are shown. 
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1.8 Importance of isoform selective HDAC inhibitors 
Until now, only two HDAC drugs, SAHA and FK-228 are approved by the FDA for the 
treatment of cutaneous T-cell lymphoma (CTCL). Many HDAC inhibitors are in the clinical 
trials. However, certain issues with the HDAC inhibitors in the clinic trials have become 
apparent, which are need to be overcome for this class of drugs to be more effective anti-cancer 
agents. The significant toxicities associated with clinically tested HDAC inhibitors in patients 
include gastrointestinal symptoms, bone marrow suppression, fatigue, cardiac arrhythmia, 
nausea, dehydration, thrombocytopenia, and anorexia.
88-92
 One hypothesis that account for 
undesired pharmacological effects
93
 is the non-specific interaction of the HDAC inhibitors with 
all or most of the class I, II, and IV HDACs due to the highly conserved catalytic active site. For 
example, SAHA and valproic acids are broad-spectrum (pan) inhibitors that target all the HDAC 
isoforms with similar potency, leading to potential side-effects.
94
 Hence, HDAC inhibitors which 
are selective to one specific HDAC isoform called "isoform selective HDAC inhibitors" can be 
used as effective anti-cancer drugs with minimal side-effects.
95
 Romidepsin, a FDA-approved 
drug is class I selective HDAC inhibitor that targets HDAC1 and HDAC2 over other HDAC 
isoforms. MS-275 (entinostat) is another class I selective HDAC inhibitor that displays potency 
against HDAC1, HDAC2, HDAC3, and HDAC9 over other HDAC isoforms, 
94
  Tubacin was 
the first HDAC6 selective inhibitor discovered using a chemical genetic screen of 7392 small 
molecules.
96
 Tu acin was shown to specifically inhi it the α-tubulin deacetylation without 
affecting the levels of histone acetylation.
96
 Using the rational drug design approach, tubastatin 
(Figure 1.7), a highly HDAC6 selective inhibitor (>1000-fold against recombinant HDACs, 
Table 1.1), was synthesized, which exploits the amino acid differences in the solvent-exposed 
region of HDAC1 and HDAC6 homology models.
35
 Similarly, SHI-1:2 
97,98
 (Figure 1.7, Table 
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1.1) was created from docking analysis of CI-994 with HDAC1 and HDAC3 homology 
structures by exploiting the difference in the amino acid sequence in the foot pocket of the 
HDAC active site. Although crystal structures of HDAC1, HDAC2, HDAC3, HDAC4, HDAC7, 
and HDAC8 are reported, the high sequence similarity among the HDAC isoforms complicates 
computer aided selective drug design.  
 Several emerging clinical trials data with isoform selective HDAC inhibitors reported 
reduced toxicity in patients relative to the pan-HDAC inhibitors. For example, hematological 
toxicity and QT internal changes were not observed in patients administered with class I 
selective HDAC inhibitors, mocetinostat and entinostat, as compared to pan-inhibitor 
SAHA.
99,100
 Overall, the clinical data of the compounds suggests that isoform specific HDAC 
inhibitors are safer with wider therapeutic index than the pan-inhibitors.  
In addition to their clinical significance, isoform selective HDAC inhibitors can also be 
valuable tools to study the role of individual HDAC isoforms in cancer biology. Trapoxin (TPX), 
a small molecule HDAC inhibitor was successfully used as an affinity probe to identify and 
isolate the first human HDAC protein, HDAC1, from nuclear extracts.
101
 Altered expression of 
genes linked to cell cycle regulation and apoptosis was observed in gene profiling studies with 
the HDAC inhibitors, which confirmed the role of HDAC proteins in tumor formation.
102,103
 
However, one major disadvantage is the available pan-HDAC inhibitors reflect the combined 
role of HDAC isoforms in carcinogenesis. Hence, isotype specific HDAC inhibitors will be 
indispensible tools in HDAC research biology.  
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Table1.1: Isoform selectivity data of HDAC inhibitors against recombinant HDAC 
isoforms (IC50 in nanomolar).
94
 
 
 
 
 
 
 
 
 
a. IC50 values are represented in micromolar. 
 
 
 
 
 
 
 
Inhibitor 1 2 3 4 5 6 7 8 9 10 11 
Broad Spectrum Inhibitors 
TSA 2 3 4 6 ND 3 5 456 6 10 - 
SAHA 68 164 48 101 ND 90 104 1.5
a
 107 - - 
Class I Selective 
FK-228 40 50 - 0.5
a 
- 14
a
 - - - - - 
Apicidin >10
a
 1.2
a
 2.3
a
 >10
a
 >10
a
 >10
a
 >10
a
 0.6
a
 >10
a
   
MS-275 181 1.2
a
 2.3
a
 >10
a
 - >10
a
 >10
a
 >10
a
 0.5
a
 - - 
CI-994 0.4
a
  0.8
a 
  >10
a
  >10
a
 - - - 
SHI-1:2 7 49 10
a
 >10
a
 >10
a
 >10
a 
>10
a
 >10
a
 - - - 
Class II Selective 
Tubacin 1.4
a
 6.2
a
 1.2
a
 17
a
 3.4
a
 4 9.7
a
 11
a
 4.3
a
 3.7
a
 3.8
a
 
Tubastatin 41.3 128 63.1 64.8 65.2 0.40 34.3 45.4 47.7 65.1 45.9 
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1.9 Current selectivity screening methods for identification of selective HDAC inhibitors 
 Several factors have complicated selective inhibitor discovery.
95
 One critical issue is the 
availability of screening assays. Current methods for screening small molecules for HDAC 
activity involve a commercially available in vitro HDAC fluorescence assay (HDAC Fluor-De-
Lys
TM
 assay kit from Biomol international
®
) that utilizes a fluorogenic peptide as HDAC 
substrate (Figure 1.8). To implement the fluorescence assay for screening small molecule for 
selectivity, individual HDAC isoforms are needed. Except HDAC8, no other HDAC isoform can 
be expressed actively in bacteria or yeast system and therefore a baclovirus system is used to 
express HDAC proteins. However, baclovirus expression is low yielding, substantially 
increasing the cost to screen small molecules against all the HDAC isoforms.
94,104,105
 An 
alternate approach utilizing the HDAC fluorescence assay involves immunoprecipitations of 
individual HDAC proteins from cellular lysates. Unfortunately, the association of HDAC 
proteins with each other in cellular lysates complicates the interpretation of the selectivity output. 
Moreover the error generated from the immunoprecipitation experiments is very high (30-
60%).
106
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Figure 1.8: Representation of HDAC Fluor-De-Lys
TM
 Assay. HDAC activity from HeLa cell 
extract on incubation with Fluor-De-Lys
TM
 HDAC substrate deacetylates the acetyl group on the 
lysine exposing the free amine of lysine. Trypsin present in the Fluor-De-Lys
TM
 developer 
cleaves at the carboxyl end of the peptide releasing the coumarin fluorophore. Excitation at 
360nm and emission at 460nm produce fluorometric signal monitored using a Genios Tecan plus 
plate reader. 
 
 Alternatively, many binding assays have been developed to identify isoform selective 
HDAC inhibitors. In one approach, Schreiber and coworkers utilized small molecule microarrays 
as a tool for screening inhibitors against recombinant HDAC isoforms.
107,108
 Albeit promising, 
the small molecule microarray method is not a direct indicator of the binding affinity of the small 
molecule for HDAC protein, with additional secondary binding assays needed to confirm. 
Overall, the high cost of the reagents and expense of robotics instrumentation make the assay 
less viable for selectivity screening in high throughput manner.
109
  
 More recently, Bantscheff and co-workers utilized a SAHA affinity probe and mass 
spectrometry to analyze the selectivity profile of 16 HDAC inhibitors with different HDAC 
complexes in a cell.
110
 Pan-inhibitor SAHA was derivatized with protein A sepharose beads to 
generate a chemical probe that aids in the capture of multiple HDAC complexes from cellular 
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lysates. Selectivity profiles of HDAC inhibitors were identified based on their interaction with 
multiple HDAC complexes in the context of cellular functions, rather than catalytic site of 
individual HDAC proteins. However, the use of mass spectrometry instrumentation and the 
effort to synthesize the affinity probe matrix make the assay low throughput for isoform 
selectivity screening. 
 Another approach which identifies the selectivity of inhibitors is a substrate independent 
TR-FRET histone deacetylase inhibitor assay format, which measures the binding affinities of 
inhibitors without the measurement of HDAC activity.
111
 Unlike the traditional fluorescence-
based HDAC activity assay that employs non-specific substrates, TR-FRET utilizes a Alex 
Fluor® 647-labelled HDAC inhibitor or tracer that binds with a high affinity to class I and IIb 
HDAC proteins. The inhibitory profile of common HDAC inhibitors with six recombinant 
HDAC isoforms was determined, however the use of expensive reagents limits the assay for 
screening large small molecule library.
111
  
  
This Thesis project 
 Isoform selective HDAC inhibitors can be potent anti-cancer drugs with minimal side-
effects, in addition can be used as pharmacological tools to study the role of individual HDAC 
proteins in disease formation. The long term goal of one of the HDAC projects in Pflum lab is to 
identify isoform selective HDAC inhibitors. Towards this main goal, we developed an high 
throughput ELISA-based HDAC activity assay to screen small molecules for isoform selectivity 
in cost-effective manner, which is described in this thesis project. Second chapter of this thesis 
project outlines the development of the ELISA-based HDAC activity and optimization of this 
assay for high throughput screening. In addition, the reliability of this ELISA-based HDAC 
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activity assay is tested by screening known HDAC inhibitors and comparing the dose-dependent 
inhibition with the reported values in the literature.  
The third chapter of the thesis project focus on the employing the developed ELISA-
based HDAC activity assay to identify isoform selective HDAC inhibitors. In this process, we 
performed a small pilot-screen of synthesized small molecule C7, C2, and C3 SAHA library 
against individual HDAC1, HDAC2, HDAC3, and HDAC6 isoforms. We identified an HDAC6 
selective inhibitor, which showed around 87-fold selectivity over class I HDAC isoforms.
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CHAPTER 2  
Development of ELISA-based HDAC Activity Assay 
As described in previous chapter, development of strictly isoform selective HDAC 
inhibitors has been complicated by inadequate screening technologies. So far, very few HDAC 
inhibitors have been screened against all the eleven HDAC proteins separately (Chapter 1, 
Section 1.10, Table 1.1). The most widely used in vitro assay for inhibitor screening is the 
HDAC Fluor-De-Lys
TM
 assay.
112
 This assay utilizes a fluorogenic peptide substrate to monitor 
the activity of deacetylase enzyme (Chapter 1, Section 1.10, Figure 1.9). Even though it is 
reliable and high throughput, the most common way of identifying selective inhibitors is using 
recombinant HDAC proteins. Baclovirus expressed recombinant HDAC proteins are obtained in 
low yield and costs around 5$ for each reaction, ultimately making the inhibitor screening using 
the HDAC Biomol substrate low throughput. Recent optimization using 384 well plates reduced 
the cost to 2.5$ for each reaction. Even then, it is not high throughput for screening large small 
molecule libraries.
113
 Another major drawback of using expensive recombinant HDAC isoforms 
is the inconsistent data. For example, apicidin showed different IC50 values against HDAC1 
recombinant proteins in two different reports (IC50 >10,000 nM or 0.7 nM).
94,114
  The data 
strongly imply the importance of screening against mammalian-cell derived HDAC isoforms, 
which are appropriate for cell-biology and clinical studies.  
 Alternatively, HDACi selectivity screening can be performed with immunoprecipitated 
mammalian HDAC proteins employing the HDAC Fluor-De-Lys
TM
 substrate. However, 
immunoprecipitation lacks the specificity because HDAC proteins were found to associate with 
each other in HeLa lysates. In addition, the 60% error generated in these experiments makes the 
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approach less reliable.
106,115,116
  
The major limitations in the available selectivity screening technologies have stalled the 
thorough identification of strict isoform selective HDAC inhibitors in a cost effective manner 
against human HDAC proteins. Hence identification of strictly isoform selective HDAC 
inhibitors will benefit cancer therapeutics. In addition, isoform selective HDAC inhibitors show 
immense potential in molecular biology field as invaluable tools for the evaluation of biological 
role of individual HDACs in disease formation. 
2.1 Prior Work 
 To obtain well-folded individual HDAC proteins for identifying isoform selective HDAC 
inhibitors, a previous Pflum lab member, Dr. Emily Aubie, performed immunoprecipitation of 
individual HDAC proteins from HeLa lysates.
117
 Unfortunately this was challenging due to 
contamination of other HDACs with the immunoprecipitated HDAC isoform (Figure 2.1A).
118
 
Sin3, NuRD, and CoREST
15,119-122
 are the three characterized co-repressor complexes of 
mammalian cells in which HDAC1/HDAC2 are known to associate with each other. HDAC3 co-
immunoprecipitated with class II HDACs, HDAC4 and HDAC7.
21,123
 Class II HDACs, HDAC4, 
HDAC5, and HDAC7 associate with HDAC3 and the catalytic activity of HDAC7 depends on 
its interaction with HDAC3.
123,124
 Therefore, to obtain individual HDAC isoforms without any 
cross contaminants, lysates were pre-cleared with protein A agarose beads (used in 
immunoprecipitation to capture antibodies) before the immunoprecipitation experiments. The 
pre-clearing method eliminated the interactions between HDAC1 and HDAC2 (Figure 2.1B) and 
proved that the HDAC proteins can be individually isolated. Except HDAC8, HDAC9, and 
HDAC11, the associations of the remaining HDAC isoforms were studied using the pre-clearing 
method (data not shown). Based on these results, it was demonstrated that the protein A agarose 
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beads are causing non-specific interactions among the HDAC isoforms. We realized by using 
polystyrene plates to immunocapture, individual HDAC proteins can be isolated without pre-
clearing the lysates. Hence we propose to micro-immunoprecipitate individual HDAC isoforms 
onto a plate and use in a ELISA-based HDAC activity assay to monitor the activity of HDAC 
proteins separately and screen for isoform selective HDAC inhibitors. 
Figure 2.1: Co-immunoprecipitation of Individual HDAC1 and HDAC2 proteins from 
HeLa Lysates. HDAC proteins were immunoprecipitated using primary HDAC antibodies 
(HDAC1 is designated by 1 and HDAC2 by 2) indicated on the bottom of the gel and western 
blot analysis by primary HDAC antibodies (on the right side of the gel). (Lysate = 10% of HeLa 
lysate used in the IP; C = Control without primary antibody) A) Immunoprecipitation without 
pre-clearing HeLa lysates. B) Immunoprecipitation of HDAC1 and HDAC2 using pre-cleared 
HeLa lysates. Data provided by Emily Aubie.
117
  
 
2.2 Results 
2.2.1 HDAC activity assay using HDAC-Fluor-De-Lys substrate 
Enzyme linked immunosorbent assay (ELISA) is a facile, sensitive, and reliable plate-
based assay best suited for detection and quantification of peptides, proteins, antibodies, and 
hormones. It is cost effective, quick to perform, and an ideal platform for high throughput 
screening technology.  The proposed HDAC activity assay is an ELISA-based high throughput 
screen designed to monitor the activity of mammalian-cell derived HDACs in miniature format 
using immunoprecipitation (Figure 2.2).
125,126
 To begin with, a secondary antibody coated 96 
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well plate was incubated with primary HDAC antibody, followed by incubation with HeLa 
lysates, which is the source of mammalian HDACs. The deacetylase activity of the affixed 
HDAC isoform in the well was monitored using the HDAC Flour-De-Lys
TM
 substrate from 
Biomol (Chapter 1, Figure 1.9).  The  ratio  of  fluorescence  signal  with  the  HDAC  enzyme  
(positive  control containing primary HDAC antibody, HeLa lysates, HDAC Fluor-De-Lys
TM
 
substrate) to the background signal (negative control containing HeLa lysates, HDAC Fluor-De-
Lys substrate but without primary HDAC antibody) was very low (data not shown). We 
concluded that the coumarin labeled HDAC Flour-De-Lys
TM
 substrate was not sensitive enough 
to detect the small amount of immunoprecipitated HDACs bound to the plate. To overcome this 
problem, we needed a brighter fluorophore that can detect the small quantity of HDAC protein 
on the plate. 
 
 
 
 
 
 
 
 
 
Figure 2.2: HDAC activity assay using HDAC Fluor-De-Lys
TM
 substrate. A. Individual 
wells of a secondary antibody coated 96 well plate were incubated with primary HDAC antibody 
(Y, light red). The respective HDAC protein (green) was pulled out from HeLa lysates, followed 
by incubation with HDAC Fluor-De-Lys
TM
 substrate (grey, structure shown in Chapter 1, Figure 
1.9). In the presence of HDAC Fluor-De-Lys
TM
 developer, the deacetylated fluorophore was 
expected to produce a signal (blue).  
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2.2.2 HDAC activity assay using R110-Lys(Ac) substrate, 3 
 Previous work on human SIRT1 activation by resveratorl showed that a rhodamine-based 
peptide substrate, p53-R110-Lys(Ac) exhibited higher sensitivity than the HDAC-Fluor-De-
Lys
TM
 substrate
127
. Based on this work, we synthesized rhodamine110 (R110)-linked acetyl 
lysine, 3 (Scheme 2.1) as a sensitive HDAC substrate to monitor the deacetylase activity of the 
HDAC proteins bound to the plate in the developed ELISA-based HDAC activity assay (Figure 
2.3). Synthesis of the R(110)-acetyl lysine substrate 3 was performed by one-step coupling of 
rhodamine 110 hydrochloride 1 with Boc-protected N-acetylated lysine 2   
Scheme 2.1: Synthesis of R110-Lys(Ac) HDAC substrate 3. 
  
Primary HDAC antibodies were affixed to secondary antibody coated plates and the 
respective HDAC isoform was pulled out from HeLa lysates. The deacetylase activity was 
monitored using R110-Lys(Ac) peptide 3, followed by addition of developer trypsin to produce a 
fluorometric change. Initial experiments using the R110-Lys(Ac) HDAC substrate in the ELISA-
based HDAC activity assay involved HDAC1 and HDAC2. The signal to background ratios for 
HDAC1 and HDAC2 were calculated to be 3.1±0.3 and 6.2±0.3, respectively (Figure 2.4). 
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Figure 2.3: HDAC activity assay using R110-Lys(Ac) substrate 3. A. Individual wells of a 
secondary antibody coated 96 well plate was incubated with primary HDAC antibody (Y, light 
red). The respective HDAC protein (green) was pulled out from HeLa lysates, followed by 
incubation with R110-acetyl lysine HDAC substrate 3 (grey) in the presence of HDAC Fluor-
De-Lys
TM
 developer, which generated a bright fluorophore (pink). 
 
 The robustness and suitability of an assay for high throughput screening (HTS) is 
determined by the signal to noise, dynamic range, and variability in the measurements. A 
screening window coefficient called Z' factor, is a simple statistical parameter that is used to the 
evaluate the quality of an assay development and optimization conditions.
128
 For an ideal high 
throughput assay, the Z' factor, which is calculated from the standard deviations and means of 
the maximum and minimum observed signal, should be within the range of 0.5-1.0.
128
 The Z' 
factor for HDAC1 and HDAC2 were calculated to be 0.38 and 0.78, respectively. The Z' factor 
for HDAC2 indicates the high throughout nature of HDAC2 activity assay. In contrast, ELISA-
based activity assay for HDAC1 assay with a modest Z' factor required further optimization. 
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Figure 2.4: HDAC1 and HDAC2 Activity Assay using R110-Lys(Ac) Substrate. Individual 
mammalian HDAC1 or HDAC2 were affixed to secondary antibody coated plates from HeLa 
cell lysates and tested for their catalytic activity using the R110-Lys(Ac) substrate 3 (Figure 2.3). 
Mean signal (positive control containing primary HDAC antibody, HeLa lysates, and HDAC 
substrate) to background (negative control containing HeLa lysates, HDAC substrate without 
primary HDAC antibody) ratios of a minimum of three independent trials with standard errors 
were plotted. 
 
2.2.3 HDAC activity assay using the HDAC GloTM substrate 
 We could overcome the limitation of low signal observed with R110-Lys(Ac) substrate 3 
in the ELISA-based assay by exploiting the recently commercially available HDAC Glo
TM
 I/II 
assay from Promega.
129
 HDAC Glo
TM
 reagent utilizes a novel luminogenic HDAC Glo
TM
 
substrate, which contains a peptide with acetylated lysine attached to aminoluciferin (Figure 
2.5B) and HDAC Glo developer that contains trypsin and ultra Glo
TM
 luciferase enzyme. 
Deacetylation of the HDAC Glo substrate by an HDAC enzyme, followed by cleavage of peptide 
by trypsin,  releases  aminoluciferin,  which  is  acted  upon  by  luciferase  to  generate  
oxyluciferin to produce a stable chemiluminescent signal (Figure 2.5A). 
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Figure 2.5: HDAC activity assay using the HDAC Glo
TM
 substrate. A. Secondary antibody 
coated or high binding polystyrene 96 well plates were incubated with primary HDAC antibody 
followed by washing and incubation with HeLa cell lysates to affix the respective HDAC 
isoform (green). HDAC Glo
TM
 reagent (blue, HDAC Glo
TM
 substrate and HDAC Glo
TM
 
developer) was added to generate a chemiluminescence signal (yellow green), which will 
indicate the deacetylase activity of the individual HDAC isoform. B. Structure of HDAC Glo
TM
 
substrate is shown. 
  
 Initial experiments involved evaluation of the sensitivity of HDAC Glo
TM
 substrate, 
along with the R110-(Ac)-Lys substrate and HDAC Fluor-De-Lys
TM
 substrate using whole HeLa 
nuclear extract. HeLa nuclear extract was incubated with the three HDAC substrates separately. 
The deacetylase activity was monitored through fluorescence signal for HDAC Fluor-De-Lys
TM 
and R110-(Ac)-Lys substrate 3, and through chemiluminescence signal for HDAC Glo
TM
 
substrate. The signal to background ratio was determined for each substrate separately. The 
HDAC Glo
TM
 substrate was found to be roughly 115-fold more sensitive compared to HDAC 
Fluor-De-Lys
TM
 substrate (HDAC Biomol) and 33-fold more sensitive than R110-(Ac)-Lys 
substrate 3 (Figure 2.6, Table A.2). Based on these results, it became evident that the HDAC 
Glo
TM
 substrate is the most sensitive substrate to detect the micro immunoprecipitated HDAC 
A B
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protein on the plate in ELISA-based HDAC activity assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Comparison of the sensitivity of HDAC substrates. Whole HeLa nuclear extract 
was incubated with HDAC Fluor-De-Lys
TM
(HDAC Biomol), R110-(Ac)-Lys substrate 3, and 
HDAC Glo
TM
 substrate followed by monitoring of deacetylase activity. Mean of signal 
(deacetylase activity with HDAC protein) to background (without HDAC enzyme) ratio of three 
independent trials and standard error was plotted (Table A.2). 
 
2.2.3.1 Optimization of HDAC activity assay for high throughput screening on secondary-
antibody coated plates 
 
Taking the lead from the evaluation of three different HDAC substrates, we optimized the 
ELISA-based HDAC activity assay for HDAC1, 2, 3, and 6 isoforms using the HDAC Glo
TM
 
substrate. To build an ELISA assay, several parameters like selection of antibody, concentration 
of antibody and antigen, plate coating, blocking conditions, incubation time and temperature at 
each step, and washing conditions were considered. Initially, to establish the ELISA-based 
HDAC activity assay for HDAC1 and HDAC2 isoforms, the optimum concentration of primary 
HDAC antibody for the most sensitive detection of HDAC deacetylase activity was determined. 
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The concentration of primary HDAC1 and HDAC2 concentrations (10µg/mL and 20µg/ mL) 
was varied at constant HeLa lysates concentration (0.1mg/ mL) with 3% BSA in 1x TBST buffer 
as the coating solution for both incubation steps. High signal to background ratio was observed 
with both the antibody concentration and hence the lowest amount of antibody (10µg/mL) was 
picked to cut the cost of the assay (Data not shown). At the constant antibody concentration of 
100 µg/mL, the optimum activity of HDAC1 and HDAC2 was determined by varying the 
amount of HeLa lysates used in the second step. Increased lysate concentration raised the 
background signal (without antibody bound), ultimately decreasing the signal to noise. 
Therefore, the lowest lysates concentration of 0.1mg/mL was employed in future experiments. 
Incubation time of the primary HDAC antibody with the 96 well plate was also important. Signal 
to background ratio was similar with HDAC1 and HDAC2 for either one hour incubation at 
room temperature or overnight incu ation at 4 ˚C. In case of HDAC3, overnight incu ation of 
primary anti ody at 4 ˚C afforded more efficient results with higher signal to background ratio 
compared to 1hr incubation at room temperature. With these results, different antibody 
incubation times were used. 
Coating is an important step in the ELISA, where a suitable primary antibody or antigen 
is adsorbed onto the surface of a 96-well plate. The amount of antibody or antigen affixed onto 
the plate depends on several factors including the incubation time, temperature, and the type of 
coating buffer. Coating buffer preserves the antibody or antigen structure and maximizes the 
adsorption to the surface of the plate. As the part of optimizing the ELISA-based HDAC activity 
assay, the coating solution was varied which included 3% BSA in 1xTBST buffer for both 
primary antibody and HeLa lysates loading (Condition 1), 10% milk in 1xTBST for antibody and 
3% BSA in 1xTBST for lysates loading (Condition 2), 10% milk in 1xTBST for both antibody 
34 
 
 
and lysates loading (Condition 3), 3% BSA in 1xTBST buffer for primary antibody and 10% 
milk in 1xTBST for lysates loading (Condition 4). Condition 1 and condition 2 afforded very low 
signal to background ratio, condition 3 enhanced the signal to background ratio, whereas 
condition 4 significantly increased the ratio for both HDAC1 and HDAC2 isoforms (Figure 
2.7A). Therefore, 3% BSA in 1xTBST buffer was found to be best coating buffer for antibody 
binding to the plates, whereas 10% milk in 1xTBST buffer was the best coating buffer for the 
HeLa lysates incubation step. However, the amount of coating protein present in the buffer 
should be minimal to prevent the masking of the antibody epitope that would hinder the binding 
of the antigen. Hence, the minimum optimum percentage of milk was determined for coating 
HeLa Lysates onto the plate which will afford sufficient HDAC activity (Figure 2.7B). Signal to 
background ratio of HDAC1 was approximately 25 when 10% milk was used as coating 
solution. Even though the signal to background ratio for both 1% milk and 0.1% milk coating 
solution was reduced to half compared to 10% milk, there was still significant HDAC signal 
observed for both the conditions, ultimately 0.1% milk was selected as the coating solution for 
HeLa lysates in future experiments. 
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Figure 2.7: Optimized coating solution for ELISA-based HDAC activity assay. A. Individual 
HDAC1 and HDAC2 affixed onto the secondary antibody coated plate and the deacetylase 
activity was monitored by luminescence. Coating solutions were varied using four different 
conditions (1-4). The four conditions used varied amounts of proteins for loading primary 
antibody and lysates (see text). B. HDAC1 was micro immunoprecipitated onto the secondary 
antibody coated plate and the deacetylase activity was monitored through luminescence. Primary 
antibody was coated to the plate in 3% BSA, whereas HeLa lysates was incubated using various 
percentage of non-fat dry milk in 1xTBST. Signal (deacetylase activity with HDAC protein) to 
background (without HDAC enzyme) ratios of one trial were plotted in both A and B. 
 
The HDAC activity assay is a capture-based ELISA and depends significantly on the 
quality of the primary HDAC antibody employed to capture HDAC isoform. For instance, the 
HDAC6 activity assay involved vast optimization with variety of primary HDAC6 antibodies to 
get efficient signal to background ratio.  Initially, primary HDAC6 antibody produced against 
amino acids 1199-1213 of the human HDAC6 sequence (Sigma, H2287) was employed. The 
antibody gave very low signal to background ratio even at using large quantities of the antibody 
(76 µg/mL) and lysates (0.8 mg/mL) concentration, which suggest the inability of the primary 
antibody to bind to the coated plate. To overcome this problem, we utilized the primary HDAC6 
antibody against the C-terminus amino acids 916-1215 of human HDAC6 sequence (Santacruz, 
sc 11420). Based on the previous data (with Sigma H2287), initially we picked the highest 
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antibody concentrations (40 ug/mL and 80 ug/mL) and varied HeLa lysate concentration. 
Together, four conditions involving different concentration of primary HDAC6 antibody and 
HeLa lysates were employed (See Figure 2.8 legend). Irrespective of the primary HDAC6 
antibody concentration (either at 40 ug/mL or 80 ug/mL), the signal to noise ratio increased with 
increase in the HeLa lysates concentration, where condition 2 and 4, with HeLa lysate 
concentartion of 0.2 mg/mL, produced optimal signal to background ratio (Figure 2.8A).  
To cut the cost of the antibody, all the future experiments with the present HDAC6 
antibody were performed at a concentration of 10 ug/mL. As shown in Figure 2.8A, increased 
lysate concentration gave increased signal, hence we monitored the activity of HDAC6 at 
constant primary antibody concentration (10 ug/mL) and varied the concentration of HeLa lysate 
(0.1 mg/mL to 0.8 mg/mL). A four-fold increase in signal to background ratio was observed 
from 0.1 mg/mL to 0.2 mg/mL of the lysates concentration. Both 0.4 mg/mL and 0.8 mg/mL 
HeLa lysates concentrations produced roughly similar signal to noise ratio. From these results, it 
is evident that signal to background ratio of HDAC6 increased with the lysates concentration 
(Figure 2.8B). For all the future experiments with the primary HDAC6 antibody from Santacruz, 
10ug/ mL of antibody concentration and 0.4mg/mL of the HeLa lysates were used to generate 
optimal HDAC6 activity.  
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Figure 2.8: Optimization of ELISA-based HDAC6 activity assay. A. HDAC6 activity assay 
at different concentration of primary antibody and HeLa lysates. In lane 1, 40µg/mL of primary 
HDAC6 antibody was incubated on a secondary antibody coated plate and 0.1mg/mL of HeLa 
lysates was added followed by monitoring the deacetylase activity through HDAC-Glo reagent. 
Lane 2: 40µg/mL of primary HDAC6 antibody and 0.2mg/mL of lysates. Lane 3: 80µg/mL of 
primary antibody and 0.1mg/mL of lysates. Lane 4: 80µg/mL of antibody and 0.2mg/mL of 
lysates. B. HDAC6 activity assay showing variation in the HeLa lysate concentration at constant 
antibody concentration of 100 µg/mL. Lane 1: 0.1mg/mL of HeLa lysates. Lane 2: 0.2mg/ mL. 
Lane 3: 0.4mg/mL and Lane 4: 0.8mg/mL of HeLa lysates. Mean percent of signal (reaction with 
HDAC antibody) to background (without HDAC antibody) ratio of one independent trial was 
plotted. 
 
With the conditions optimized for the ELISA-based HDAC activity assay, the 
deacetylase activity of individual HDACs affixed onto the plate was monitored using HDAC 
Glo
TM
 reagent and the signal to background ratio of each HDAC isoform was determined 
separately (Figure 2.9). Signal (reaction with antibody) to background (reaction without 
antibody) ratio for HDAC1, HDAC2, HDAC3, and HDAC6 was calculated to be 23±2, 34±1, 
4.3±0.2, 7.1±0.7, respectively (Figure 2.9). The Z' factor for HDAC1, HDAC2, HDAC3, and 
HDAC6 were calculated to be 0.72, 0.66, 0.69, and 0.76, which indicates a suitable and robust 
high throughput assay. Coefficient of variation is a dimensionless parameter which defines the 
extent of variability. The higher the coefficient of variation, the greater is the variability; the 
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lower the CV, the smaller the variability, indicating an appropriate high throughput assay. For a 
ideal high throughput assay, the coefficient of variation is expected to be less than 10%. The 
calculated coefficient of variations of HDAC1, HDAC2, HDAC3, and HDAC6 isoforms were 
found to be 8.7%, 11%, 8.4%, and 5.3%, respectively, indicative of a ideal high throughput assay 
for the screening of small molecule inhibitor libraries. In addition, the developed ELISA-based 
HDAC activity assay is inexpensive and costs approximately $0.99 per reaction ($0.33 for plate, 
$0.16 for antibody, $0.50 for HDAC Glo
TM
 reagent) compared to the traditional commercially 
available screening method using recombinant HDAC isoforms ($5 per each reaction). 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: ELISA-based HDAC1, HDAC2, HDAC3, and HDAC6 Activity Assay. 
Individual mammalian HDAC1, HDAC2, HDAC3 and HDAC6 from HeLa cell lysates were 
affixed to secondary antibody plates (Figure 2.5) and tested for their catalytic activity using 
HDAC activity assay. Mean signal (reaction with HDAC protein, primary HDAC antibody, 
HDAC Glo
TM
 substrate) to background (reaction with HDAC protein, HDAC Glo
TM
 substrate, 
but without primary HDAC antibody) ratio of a minimum of three independent trials with 
standard errors was plotted (Table A.5, A.6, A.7, and A.8). 
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Over the course of time, the reactions containing lysates, primary HDAC6 antibody, and 
HDAC Glo
TM
 reagent gave very low signal, indicating problem with the primary HDAC6 
antibody.  The signal to background ratio in the HDAC6 activity assay was very low in 
comparison with the previous results (Figure 2.8 and Figure 2.9). In order to obtain reliable 
HDAC6 signal, we came across a primary HDAC6 monoclonal antibody (Novus biological, 
H00010013-M13), which is produced against whole human HDAC6. HDAC6 activity assay was 
optimized successfully with this antibody generating excellent signal to background ratio at 
10µg/mL of antibody and 0.5mg/mL of the lysates. Unfortunately, after a couple of weeks of use 
the antibody gave very low signal to noise ratio in the ELISA-based activity assay. To overcome 
this limitation we selected the same monoclonal antibody manufactured from a different and 
more reliable company, Sigma Aldrich (SAB1404771). At first the HDAC6 activity assay was 
optimized by varying the HeLa lysate concentration at constant antibody concentration of 
10µg/mL. The signal to background ratio increased five-fold from 0.5mg/mL to 1mg/mL of the 
lysate concentration (Figure 2.10A). The next step was to optimize the antibody concentration (2 
fold dilution, 0.63µg/mL to 10µg/mL) at constant lysate concentration of 1mg/mL. The signal to 
background ratio increased only two-fold from 0.63µg/mL to 10µg/mL, which indicate the need 
of only minimum amount of antibody concentration to achieve satisfactory HDAC6 signal 
(Figure 2.10B). Hence, to cut the cost of the assay for HDAC6 isoform, we picked 2 µg/mL  of 
primary HDAC6 antibody for future trials and monitored the deacetylase activity with 1mg/mL 
of HeLa lysate. 
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Figure 2.10: Optimization of ELISA-based HDAC6 activity assay using a monoclonal 
HDAC6 antibody. A. HDAC6 activity assay at constant concentration of primary antibody 
(10µg/mL) and varied HeLa lysates concentration. Lane 1: 0.5mg/mL of HeLa lysates. Lane 2: 
1mg/mL. Lane 3: 2mg/mL and Lane 4: 4mg/mL of HeLa lysates. B. Optimization of the 
concentration of primary HDAC6 antibody at constant concentration of HeLa lysates (1mg/mL). 
Lane 1: 10µg/mL of primary HDAC antibody. Lane 2: 5µg/ mL. Lane 3: 2.5µg/mL and Lane 4: 
1.3µg/mL Lane 5: 0.63µg/mL of primary HDAC6 antibody. Mean signal (reaction with 
antibody) to background (reaction without antibody) ratio of one independent trial was plotted. 
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2.2.3.2 Optimization  of  HDAC  activity  assay (HADC1, HDAC2, and HDAC6)  for  high  
throughput  screening  on  high-binding polystyrene plates 
 
To reduce the cost of the assay for high throughput screening, we moved to the use of 
high-binding polystyrene plates for capture of the primary HDAC antibody instead of secondary 
antibody coated plates. Initially to coat the plate with primary HDAC antibodies, 3% BSA in 
1xTBST buffer was used, but very low signal to background ratio was observed (data not 
shown). Later 0.2M carbonate/0.2M bicarbonate at pH 9.6 buffer was used for coating HDAC 
antibody (10µg/mL for HDAC1, 2 and 2 µg/mL for HDAC6) onto the polystyrene plates for one 
hour at room temperature and the unbound surface of the well was blocked subsequently. 
Blocking, an important step in immunoassay procedure, eliminates the unoccupied sites on the 
micro plate from non-specific binding of HDAC proteins. Different types and composition of 
blockers like 3% BSA, 10% BSA, 5% non-fat dry milk, 10% non-fat dry milk in 1xTBST buffer, 
and commercially available super blocking buffer (Thermo Scientific) were tested for the 
effective blocking. Among them, 5% and 10% non-fat dry milk gave the lowest background 
compared to the other blocking conditions. Therefore, the lowest amount of blocker, 5% non-fat 
dry milk, was selected as the blocking agent in subsequent experiments using polystyrene plates.  
 
 The next step involved incubation of the antibody-bound wells with HeLa lysates 
(0.1mg/mL for HDAC1, 2 and 1mg/mL for HDAC6), in 0.1% milk in 1xTBST buffer to affix the 
respective HDAC enzyme, followed by addition of HDAC Glo
TM
 substrate to monitor the 
deacetylase activity. Poor binding of HDAC3 antibody with the polystyrene plate gave very low 
signal to noise, therefore all the future experiments with HDAC3 were performed on secondary 
antibody coated plates as described earlier (Figure 2.9). Using high binding polystyrene plates, 
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signal to background ratio for HDAC1, HDAC2, and HDAC6 was calculated to be 28±5.5, 
92±9.9, and 8.4±0.5, respectively (Figure 2.11, Table A.9, A.10, and A.11). The Z' factor for 
HDAC1, 2, and 6 were calculated to be 0.64, 0.74, and 0.70 respectively, which indicates an 
ideal and robust high throughput assay for inhibitor screening. The calculated coefficient of 
variations of HDAC1, HDAC2, and HDAC6 isoforms were found to be 11%, 8%, and 8%, 
respectively demonstrating an ideal HTS assay for screening small molecule inhibitor libraries. 
At this point the cost of the assay is $0.64 per reaction ($0.04 for polystyrene plate, $0.16 for 
antibody, $0.44 for HDAC Glo
TM
 reagent), which allows to screen ligands for selectivity in cost 
effective manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: ELISA-based HDAC1, HDAC2, and HDAC6 Activity Assay. Individual 
mammalian HDAC1, HDAC2, and HDAC6 were affixed to the high binding polystyrene plates 
from HeLa cell lysates and tested for their catalytic activity using the HDAC Glo
TM
 reagent. 
Mean signal (reaction with HDAC protein, primary HDAC antibody, and HDAC Glo
TM
 reagent) 
to background (reaction with HDAC protein and HDAC Glo
TM
 reagent, but without primary 
HDAC antibody) ratio of a minimum of three independent trials with standard errors were 
plotted (Table A.9, A.10, and A.11). 
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2.2.3.3 Testing of known HDAC inhibitors 
With the optimized high throughput HDAC activity assay in hand, we next moved to 
testing known small molecule HDAC inhibitors. To begin with we chose three inhibitors with 
different selectivity profiles against the HDAC isoforms, SAHA,
80
 apicidin,
94,130
 and tubastatin.
35
 
SAHA is an FDA-approved drug for treatment of T-cell lymphoma, and a pan-inhibitor targeting 
most of the HDAC isoforms with equal potency. Apicidin is a class I selective HDAC inhibitor 
targeting mainly HDAC1, HDAC2, and HDAC3 isoforms. Tubastatin is a class IIa selective 
HDAC inhibitor active against HDAC6 isoform. 
Using the developed ELISA-based HDAC activity assay, HDAC1, HDAC2, and HDAC6 
isoforms were  affixed  to the high binding polystyrene 96-well plate (Figure 2.11), and HDAC3 
was immunoprecipitated onto a secondary antibody coated 96-well plate (Figure 2.9). The  above  
inhibitors  were  incubated separately with each isoform at a concentration of 1µM. Single 
concentration screening of small molecules will give a broad selectivity profile against the 
proteins and mimic the strategy for high throughput screening. The remaining deacetylase 
activity of the HDAC isoforms was determined by adding the luminogenic HDAC Glo substrate. 
Percent deacetylase activity of the individual HDAC isoforms was determined by dividing the 
signal of the reaction with primary HDAC antibody, HeLa lysates, HDAC inhibitor, and HDAC 
Glo
TM
 reagent to the signal of the reaction containing all the reagents as former but without the 
HDAC inhibitor and multiplied by 100 (Figure 2.12). 
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Figure 2.12: Isoform Selectivity Screening of Known HDAC Inhibitors. Isoform selectivity 
screen of SAHA, apicidin, tubastatin against individual immunoprecipitated human HDAC1, 
HDAC2, HDAC3, and HDAC6 at single concentration of 1µM is shown here. Mean percent 
deacetylase activity was calculated by dividing the signal of the reaction with inhibitor to signal 
of the reaction without inhibitor and all other reagents and multiplied by 100. A minimum of 
three independent trials with standard errors were plotted (Table A.12). 
 
In accordance with the reported data, SAHA inhibited the four HDAC isoforms equally at 
1µM single concentration.
94,97,130
 The percent signal to background (remaining deacetylase 
activity) of HDAC1, HDAC2, HDAC3, and HDAC6 were calculated to be 8.9±0.2, 8.3±0.2, 
14±3.0, and 7.9±2.0, respectively. Apicidin preferentially inhibited class I HDACs over HDAC6 
isoform,
94,114,130
 with percent signal to background of 3.6±0.3, 2.1±0.2, 31±5, and 81±0.1 for 
HDAC1, HDAC2, HDAC3, and HDAC6 respectively.  Class II selective HDAC inhibitor, 
tubastatin selectively targeted HDAC6 over class I HDAC isoforms (Figure 2.12) consistent with 
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the prior results.
35
 The obtained percent signal to background for HDAC1, HDAC2, HDAC3, 
and HDAC6 were 60±7, 81±5, 81±4.7, and 14±6.0, respectively. 
With the reproducibility of selectivity profiles of SAHA, apicidin, and tubastatin against 
HDAC1, HDAC2, HDAC3, and HDAC6 isoforms, our next aim was to determine the IC50 
values of the above inhibitors and compare with the already reported IC50 values. Serially diluted 
concentrations of the small molecules were incubated with individual HDAC isoforms 
immunoprecipitated using the HDAC activity assay and the remaining deacetylase activity was 
monitored using the HDAC Glo
TM
 reagent. The percentage remaining deacetylase activity at 
each small molecule concentration was calculated using against the deacetylase activity without 
HDAC inhibitor.  
As reported, SAHA inhibited all the four HDAC isoforms with equal potency, which is 
indicated by the dose dependent inhibition experiments against each of the HDAC isoform 
tested. The IC50 values of SAHA for HDAC1, HDAC2, HDAC3, and HDAC6 were 33±1, 96±1, 
20±0.3, and 33±2.7, respectively (Figure 2.13, Table 2.1). The obtained IC50 values are 
consistent with the reported values against human-cell derived isoforms (30±9, 170±51, 57±17, 
and 43±13nM, respectively)
97,130
 and baclovirus expressed recombinant proteins (68±14, 
164±45, 48±17, and 90±26nM, respectively).
94
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Figure  2.13: Dose Dependent Curves of SAHA with Individual HDAC1, HDAC2, HDAC3, 
and HDAC6 Isoforms. Mammalian individual HDAC isoforms were immunoprecipitated from 
HeLa cell lysates in HDAC activity assay and the catalytic activity of each HDAC isoforms was 
tested in the absence and the presence of varying concentrations of SAHA (Table A.13, A.14, 
A.15, and A.16). IC50 was determined by fitting data to a sigmoidal curve using Kaleidograph 
4.0 (Synergy Software) with error bars depicting the standard error of at least three independent 
trials. 
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Table 2.1: IC50 values (nM) of SAHA, Apicidin, and Tubastatin using the ELISA-based 
HDAC activity assay 
a. IC50 values are against mammalian cell-derived HDACs. ND-not determined 
  
 Apicidin showed selectivity for class I HDACs with IC50 values of 6±0.1, 5.3±0.02, and 
3.6±0.02 against HDAC1, HDAC2, and HDAC3, respectively (Figure 2.14). The IC50 values 
were consistent with the reported values against mammalian HDAC1 and HDAC3 isoforms 
(0.023 and 0.0093, respectively).
130
 The IC50 value of apicidin with HDAC6 was not determined 
due to randomness in the inhibition values among various trials. In the dose dependent studies, 
complete inhibition of HDAC6 was not achieved even at high concentration of small molecule 
(Data not shown). One explanation was that apicidin is very a poor inhibitor of HDAC6 isoform 
making it harder to get dose-dependent inhibition values which is consistent with previous 
reported values (4.3µM against mammalian HDAC6 and >10µM with recombinant 
HDAC6).
94,130
  
Compound   IC50 values (nM)
a
 
HDAC1 HDAC2 HDAC3 HDAC6 
SAHA 33±1.4 96±1.0 20±0.3 33±2.7 
Apicidin 6.0±0.1 5.3±0.02 3.6±0.02 ND 
Tubastatin 2700±200 3900±400 2900±500 31±4.0 
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Figure 2.14: Dose Response Curves of Apicidin with Individual HDAC1, HDAC2, and 
HDAC3 Isoforms. Mammalian individual HDAC isoforms are immunoprecipitated from HeLa 
cell lysates using HDAC activity assay and the catalytic activity of each HDAC isoforms was 
tested in the absence and presence of varying concentrations of Apicidin. IC50 was determined by 
fitting data to a sigmoidal curve using Kaleidograph 4.0 (Synergy Software) with error bars 
depicting the standard error of more at least three independent trials (Table A.17, A.18, A.19). 
 
Finally, tubastatin showed expected HDAC6 selectivity over HDAC isoforms.  The dose 
dependent inhibition values obtained from HDAC activity assay using human HDAC1, HDAC2, 
HDAC3, and HDAC6 were 2.7±0.2µM, 3.9±0.4µM, 2.9±0.5µM, and 31±4nM, respectively, 
with 87-fold selectivity for HDAC6 over HDAC1 isoform (Figure 2.14). The IC50 values 
reported against baclovirus expressed HDAC1, HDAC2, HDAC3, and HDAC6 proteins were 
16.4±2.6, >30, >30, and 0.015±0.001µM, respectively showing 1000-fold HDAC6 selective 
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inhibitor.
35
 The inconsistent results in the fold selectivity of recombinant HDAC isoforms and 
human HDAC isoforms strongly emphasize the importance of screening small molecules against 
human-derived HDAC proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: Dose Dependent Curves of Tubastatin with Individual HDAC1, HDAC2, 
HDAC3, and HDAC6 Isoforms. Mammalian individual HDAC isoforms were 
immunoprecipitated from HeLa cell lysates using HDAC activity assay and the catalytic activity 
of each HDAC isoforms was tested in the absence and presence of varying concentrations of 
Tubastatin. IC50 was determined by fitting data to a sigmoidal curve using Kaleidograph 4.0 
(Synergy Software) with error bars depicting the standard error of more at least three 
independent trials (Table A.20, A.21, A.22, and A.23) 
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2.3 Validation of ELISA-based HDAC activity assay 
As described earlier in Chapter 2, Section 2.1 (Figure 2.1), immunoprecipitation of 
individual HDAC isoforms is challenging because of the interaction of HDAC isoforms with 
each other. For example, HDAC1 and HDAC2 are known to co-immunoprecipitate with each 
other and Class II HDACs interact with HDAC3. Dr. Emily Aubie, previous lab member was 
successfully able to demonstrate the absence of non-specific interactions of HDAC isoforms 
when HeLa lysates pre-incubated with protein A agarose beads (used to capture primary HDAC 
antibody) were used in immunoprecipitation (Figure 2.1).
117
 Taking lead from the above results, 
an ELISA-based HDAC activity assay that employs polystyrene plates was designed (Section 
2.2.3, Figure 2.5). Individual HDAC1, HDAC2, HDAC3, and HDAC6 isoforms were 
immunocaptured on a polystyrene well and the deacetylase activity was monitored in a miniature 
format (Figure 2.9 and Figure 2.11). The selectivity profile of three known HDAC inhibitors 
against the immunoprecipitated HDAC isoforms was also evaluated, which gave consistent 
results with the reported literature (Section 2.2.3.3, Figure 2.12).  
The ELISA-based HDAC activity assay is a sensitive and feasible method to screen small 
molecule HDAC inhibitors for isoform selectivity. But one limiting factor of the assay is the 
known interactions of HDAC isoforms with each other, which would give inconsistent results in 
selectivity screening of small molecules.  However, in the ELISA-based HDAC activity assay, 
individual HDACs showed different activity which demonstrate that the isoforms are not co-
immmunoprecipitating with each other (Figure 2.9 and Figure 2.11). To further prove the 
absence of interactions among HDAC isoforms, a novel co-immunoprecipitation sandwich 
ELISA was designed (Figure 2.16). Individual HDACs are immunocaptured similar to ELISA-
based HDAC activity assay (Section 2.2.3). After the capture of individual HDACs, a detection 
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primary HDAC antibody (recognizes a different epitope compared to capture antibody) was 
added that interact with the pulled out HDAC isoform. Addition of a secondary antibody labelled 
with horse radish peroxidase (HRP) followed by chemiluminescent substrate would give a 
luminescence signal (Figure 2.16). In order to show that individual HDACs are not co-
immunoprecipitating with each other, a detection primary HDAC antibody which is not specific 
to the immunocaptured HDAC isoform was added followed by addition of HRP-labeled 
secondary antibody.  If the HDACs are not interacting with each other, then the 
chemiluminescent substrate would not give any signal (Figure B). However, lack of perfect 
matched antibody pairs for individual HDAC proteins resulted in diminished signal in the 
positive control (Lane 6, Figure 2.17) for the co-immunoprecipitation sandwich ELISA limiting 
the study of HDAC interactions with each other using this method.   
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Figure 2.16: Co-immunoprecipitation Sandwich ELISA. High binding polystyrene 96 well 
plates were incubated with primary HDAC antibody followed by washing and incubation with 
HeLa cell lysates to affix the respective HDAC isoform (green). Primary HDAC detection 
antibody (brown) which recognizes a different epitope on the captured HDAC isoform was 
incubated followed by washing. Secondary antibody labeled with horse radish peroxidase (blue) 
was added and incubated followed by washing. A chemiluminescent substrate (grey) was added 
to generate a chemiluminescence signal (yellow), which will indicate the capture of the HDAC 
isoform on the plate. In order to study HDAC isoform interactions, detection antibody which 
recognizes a different HDAC isoform was added and the signal was monitored. In the absence of 
interactions, luminescence signal will be diminished.  
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Figure 2.17: Coimmunoprecipitation of HDAC1. High binding polystyrene 96 well plates was 
incubated with primary HDAC1 antibody followed by washing and incubation with HeLa cell 
lysates to affix the respective HDAC1 isoform. Primary HDAC1 detection antibody which 
recognizes a different epitope on the captured HDAC1 isoform was incubated followed by 
washing. Secondary antibody labeled with horse radish peroxidase was added and incubated 
followed by washing. A chemiluminescent substrate was added to generate a chemiluminescence 
signal which will indicate the capture of the HDAC isoform on the plate. Luminescence signal of 
one independent trial was plotted. 
 
In order to overcome the limitations of co-immunoprecipitation sandwich ELISA, an 
alternate method to study the HDAC isoform interactions was established. In this assay, 
individual HDACs were immunocaptured onto the polystyrene plates similar to ELISA-based 
HDAC activity assay (Section 2.2.3, Figure 2.5) followed by elution of the HDAC protein. The 
eluted HDAC protein was separated on SDS-PAGE and western blotted with primary HDAC 
Lane 1 2 3 4 5 6
HDAC1(10g/mL) - - - + + +
Lysates (0.1mg/mL) - - + + - +
HDAC1 (1g/mL) - + + - + +
2 HRP (25ng/mL) + + + + + +
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antibodies. However, ELISA-based HDAC activity assay is a microimmunoprecipitation assay 
and very small amount of HDAC protein is captured onto the plate which ultimately was not 
sensitive enough to detect the interactions on the western blot (Data not shown). The assay needs 
to be optimized further to overcome the sensitivity issues and additional work is underway in our 
lab to establish this method. Once the assay is well optimized, interactions of all the HDAC 
isoforms can be studied more rigorously.  
 
 
 
 
Figure 2.16: Alternate Co-immunoprecipitation Assay. High binding polystyrene 96 well 
plates were incubated with primary HDAC antibody followed by washing and incubation 
with HeLa cell lysates to affix the respective HDAC isoform (green). HDAC isoform was 
eluted and the sample was run on SDS-PAGE electrophoresis followed by western blotting 
with primary HDAC antibody. 
  
2.4 Discussion 
 Isoform selective HDAC inhibitors have long been hypothesized to overcome the side-
effects of the known HDAC-target drugs like SAHA and FK-228, in addition to being valuable 
tools in chemical genetics to study the role of individual HDAC isoforms in disease formation. 
Currently the most widely used in vitro assay to screen HDAC inhibitors for selectivity is the 
commercially available HDAC fluorimetric assay from Enzo life science. However, the use of 
recombinant proteins as the source of HDAC isoforms limits the assay to low throughput and 
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prohibitively expensive to screen a single small molecule against all the individual HDAC 
isoforms. On the top of this, the recombinant HDAC proteins are not true reflection of 
mammalian HDAC proteins generating disparity in selectivity outcome (Table 1.1). To 
overcome the serious limitations of the current assay for selectivity screening, we developed an 
inexpensive and high throughput ELISA-based HDAC activity assay that can assess the 
biological activity of compounds with mammalian cell-derived HDAC proteins. The major 
prerequisite is the bound primary HDAC antibody which can pull the respective HDAC proteins 
from HeLa cellular lysates. 
 Initial experiments towards the development of the ELISA-based HDAC activity assay 
employed HDAC Fluor-De-Lys
TM
 substrate from Enzo life science (Figure 2.1). But the major 
drawback was the insensitivity of the HDAC substrate to detect minute picogram of HDAC 
protein affixed onto the plate (Data not shown). Hence a more sensitive rhodamine-based HDAC 
substrate 3 was synthesized, which is a brighter fluorophore than the coumarin of HDAC Fluor-
De-Lys
TM
 substrate. The (R110)-linked acetyl lysine HDAC substrate was able to detect the 
minute amount of HDAC1 and HDAC2 protein immunoprecipitated on the plate (Figure 2.3). 
The signal dynamic range for the ELISA-based HDAC2 activity assay was ideal for high 
throughput screening whereas for HDAC1 activity assay it was below the perfect range for an 
ideal assay. To overcome this drawback and detect other immunoprecipitated HDAC isoforms 
for the activity assay, we utilized HDAC Glo
TM
 substrate from Promega, which was found to be 
around 100-fold more sensitive than Biomol (HDAC-Fluor-De-Lys
TM
 substrate) and 30-fold 
more sensitive than the synthesized (R110)-linked  acetyl  lysine HDAC substrate 3 (Figure 2.4). 
With the HDAC Glo substrate, the ELISA-based HDAC1, HDAC2, HDAC3, and HDAC6 
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activity assay was established for high throughput screening of ligands for selectivity (Figure 2.9 
for HDAC3 and 2.11 for HDAC1, HDAC2, and HDAC6). 
 The established ELISA-based HDAC activity assay was validated for high throughput 
selectivity screening with the three known HDAC inhibitors. The inhibitory activity of SAHA 
and apicidin using the ELISA assay were consistent with the reported data from the mammalian 
HDAC isoforms. Interestingly, apicidin displayed different IC50 values against recombinant 
HDAC1 isoform in two different publications (>10,000 nM, 0.7 nM).
94
 The ELISA-based 
HDAC activity assay successfully resolved the divergence in the apicidin data and confirmed the 
nanomolar potency against HDAC1. Finally, tubastatin was tested for the first time against 
mammalian HDAC isoforms using the ELISA assay.  Tubastatin displayed HDAC6 selectivity 
consistent with the earlier report from baclovirus expressed HDACs, however, the extent of 
selectivities was not reproducible (1000-fold HDAC6 for baclovirus-expressed, whereas only 87-
fold HDAC6 selectivity with human HDACs). The above variations in the IC50 data from 
recombinant HDACs strongly suggest the importance of screening small molecule using the 
mammalian derived HDAC isoforms. Another major advantage of the ELISA-based HDAC 
activity assay is the reduced cost of the reagents in comparison to the purified HDAC proteins 
from baclovirus expression systems used in HDAC-Fluor-De-Lys
TM
 assay. Overall, the use of 
HeLa lysates as the source of human HDACs and the reduced cost of the ELISA-based HDAC 
activity assay allows for high throughput screening of small molecules for HDAC isoform 
selectivity.  
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2.5 Experimental methods 
 
2.5.1 Reagents 
 
 All reagents were purchased from Fisher Scientific, Acros Organics or Sigma Aldrich 
unless otherwise noted. Thin layer chromatography was performed using 6 Å, 25 μm Partisil® 
K6F fluorescent indicator plates (Fisher). Flash chromatography was carried out using 60 Å, 
230-400 mesh silica gel (Whatman). Purification of compounds using HPLC was performed with 
a Symmetry® Reverse Phase C 8 5μm column (4.6x 5  mm Diameter) on a Waters 1525 
Binary HPLC pump and Waters 2998 Photodiode Array detector. Non-fat dried milk was 
purchased from the Biorad. Bovine serum albumin was purchased from Jackson 
immunoresearch. Primary HDAC1 (H3284), HDAC2 (H3159), HDAC3 (H3034), HDAC6 
(SAB1404771) were purchased from Sigma Aldrich (Table 2.2). 
 
Table 2.2: Antibodies used in ELISA-based HDAC activity assay 
HDAC Antibody Amount used Source 
1 100 µg/mL  Sigma (H3284) 
2 100 µg/mL Sigma (H3159) 
3 100 µg/mL Sigma (H3034) 
6 76µg/ mL Sigma (H2287) 
6 100 µg/mL SCBT(Sc-11420) 
6 2µg/ mL Novus Biologicals (H00010013-M13) 
6 2µg/ mL Sigma (SAB1404771) 
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2.5.2 General Equipment 
 
 Standard biochemical equipment includes centrifuges (Eppendorf models 5415D and 
5810R), bacterial incubator/shaker (New Brunswick Scientific C25 Incubator Shaker Classic 
Series), a Tecan GENios Plus spectrophotometer, a VWR rocking platform, and a Barnstead 
Thermolyne Labquake shaker rotisserie. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.3 Preparation of Rh110-Lys(Ac) HDAC substrate 3 
 
Di-tert-butyl((2R,2'R)-((3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)bis 
(azanediyl))bis(6-acetamido-1-oxohexane-2,1-diyl))dicarbomate, 3 
 
 Boc-protected N-acetylated lysine 2 (100mg, 0.27 mmol), dicyclohexylcarbodiimide 
(197mg, 0.95 mmol), and dimethylaminopyridine (133mg, 1.1 mmol) were combined in DCM 
(20 mL) and stirred at 0 C for 15min. The reaction mixture was allowed to warm to room 
temperature and then Rhodamine 110 hydrochloride 1(50mg, 0.13 mmol) was added portion 
wise. The whole mixture was stirred at room temperature. After 48h, the solvent was evaporated 
and residue was subjected to column chromatography (silica) to get the desired product using 
4% MeOH-DCM as the mobile phase. But the desired product still had some impurities and was 
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further purified using HPLC and a gradient of 90% Buffer A to 10% Buffer A over 20 min at 
1.0 mL/min flow at room temperature. Buffer A is water with 0.1% TFA and buffer B consists 
of HPLC grade acetonitrile, and the compound eluted at 13 minutes. The compound was 
characterized using MALDI MS analysis, which showed characteristic peak at 871.7. 
 
 
2.5.4 HeLa cell lysis 
 
 HeLa-S3 cell line purchased from Biovest Inc (1 x 10
9
 cells frozen at -80 C) were lysed 
in Jurkat Lysis Buffer (JLB, 9 mL; 50 mM Tris-HCl, pH 8.0, 10% glycerol, 150 mM NaCl, 0.5% 
Triton X-100) containing 1X Calbiochem protease inhibitor cocktail set V with rotation at 4 C 
for 30 min. Cell debris was removed by centrifugation at 12000 rpm at 4 C for 30 min and 
protein content (mg/mL) of the supernatant was determined using Bio-Rad protein assay 
(Bradford reagent catalog number 500-006). The concentration of HeLa lysates was usually 
between 5-15mg/ mL. The lysates were stored at -80 C in 200µL aliquots. 
 
 
2.5.5 ELISA-based HDAC activity assay on secondary antibody coated plates using 
R110-Lys(Ac) substrate 3 
 
 Secondary antibody coated 96-well opaque plates (Thermo Scientific) were incubated 
with primary HDAC1 (H3284, Sigma) or HDAC2 (H3159, Sigma) antibody (100 µL of 100 
µg/mL in 3% BSA in 1X TBST buffer (150 mM Tris HCl, 50 mM NaCl, pH 7.4, 0.05% Tween-
20, 0.1% BSA)). The plate was rocked (3 rpm, VWR rocking platform) for 1 hr at room 
temperature. After one hour, the contents of the wells were emptied by inversion of the plate, 
followed by washing three times with 1X TBST buffer using a squirt bottle (the buffer was squirt 
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slowly to full capacity of the well without spilling the contents between two wells) and inversion 
to remove buffer. An additional wash with 300µL of 1X TBST buffer was performed with 
rocking (3rpm, VWR rocking platform) at room temperature. After 5 minutes, the buffer was 
removed by inversion of the plate and washed a final time with 1X TBST buffer. The wells were 
dried by repeated tapping on a stack of filter papers.  
 In the next step, the wells were incubated with HeLa lysates (100 µL of 100 µg/mL in 0.1 
% non-fat dry milk in 1X TBST buffer) for one hour at 4 C with rocking (600rpm), followed by 
washing the plate with 1X TBST wash buffer (3 times) and an additional time for 5 min on a 
rocker, as described in previous paragraph. After removal of buffer from the final wash by 
inversion and additional wash by squirting the buffer into wells and inverting the plate 
immediately, the plate was repeatedly tapped onto the filter paper to completely dry the wells.  
 After immunocapture of HDAC1 or HDAC2, to the wells was added HDAC-Fluor-De-
Lys
TM
 buffer (25 µL, 50 mM Tris/Cl, pH 8.0, 137 mM  NaCl, 2.7 mM KCl, 1 mM MgCl2) and 
Rh110-Lys(Ac) substrate 3 (25 µL, 100 µM final concentration), and incubated for 45 minutes 
with shaking at 30 C. The reaction was then quenched by addition of HDAC-Fluor-De-LysTM 
developer (2.5µL of 20X diluted to 50µL in HDAC-Fluor-De-Lys
TM
 buffer) and the plate was 
allowed to stay in the dark for an additional 5 minutes. Deacetylase activity was measured as 
fluorescence using a Geniosplus Fluorimeter (Tecan) with excitation at 485 nm and emission at 
535 nm. Mean of signal (deacetylase reaction with primary HDAC antibody, HeLa lysates, 
Rh110-Lys(Ac) substrate 3, and HDAC-Fluor-De-Lys
TM
 developer) to background (reaction 
with HeLa lysates, Rh110-Lys(Ac) substrate 3, HDAC-Fluor-De-Lys
TM
 developer, but without 
primary HDAC antibody) ratio was determined as shown in Chapter 2, Section 2.2.2, Figure 2.4, 
Table A.1, and A.2.  
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2.5.6 Comparison of HDAC substrates 
 In case of HDAC Biomol substrate (Enzo Life Sciences, BML, KI105-0050, HDAC 
Fluor-De-Lys
TM
 substrate) and Rh110-Lys(Ac) substrate 3, HeLa lysates (4 µg of total protein) 
were placed in separate 1.5 mL Eppendorf tubes and diluted to a final volume of 25 µL in HDAC 
Fluor-De-Lys
TM
 assay buffer (Enzo Life Sciences, BML, KI143-0020, 50 mM Tris/Cl, pH 8.0, 
137 mM NaCl, 2.7mM KCl, 1 mM MgCl2). 25 µL of HDAC Fluor-De-Lys
TM
 substrate (Enzo 
Life Sciences, BML, KI105-0300, 50) was added to one tube, 25 µL of Rh110-Lys(Ac) HDAC 
substrate 3 (25 µL) was added to the second tube and incubated at 30 C for 30 minutes. To a 
third tube for the HDAC Glo
TM
 substrate (Promega), the same amount of HeLa lysates was 
diluted to final volume of 25 µL in HDAC Glo assay buffer (25 mM Tris buffer, pH 8.0, 137 
mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 1% v/v Triton X-100)
129
 and 25 µL of HDAC Glo 
reagent (Promega, the HDAC Glo reagent was prepared by premixing 1 mL of the HDAC Glo
TM
 
substrate (100 µM) and 1 µL of the HDAC Glo developer  and storing at -20 C in aliquots until 
needed) was added and incubated at room temperature for 30-45 min. Negative control was set 
up by addition of HDAC-Fluor-De-Lys
TM
 buffer (25 µL) instead of HeLa lysates, and all other 
components in the case of the HDAC Biomol and Rhodamine substrate 3. In case of HDAC Glo 
substrate, HDAC Glo
TM
 assay buffer (25 µL) was added in the place of HeLa lysates. 
 The contents of the tube containing HDAC Fluor-De-Lys
TM
 substrate was transferred to 
the wells of 96-well black opaque plate (Fisher) and 50µL of HDAC Fluor-De-Lys
TM
 developer 
(Enzo Life Sciences, 2.5µL of 20X diluted to 50µL in HDAC assay buffer) was added and 
incubated for additional 5 minutes in dark at room temperature. The deacetylase activity of the 
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HeLa lysates was measured as fluorescence using Geniosplus Fluorimeter with excitation at 360 
nm and emission at 465 nm.  
 The contents of second tube containing Rh110-Lys(Ac) substrate 3 was transferred to a 
96-well black opaque plate and the 50µL of HDAC Fluor-De-Lys
TM
 developer (Enzo Life 
Sciences, 2.5µL of 20X diluted to 50µL in HDAC assay buffer) was added and incubated for 
another 5 minutes in dark at room temperature. The deacetylase activity of the HeLa lysates was 
measured as fluorescence using Geniosplus Fluorimeter with excitation at 485 nm and emission 
at 535 nm. 
 The contents of the tube with HDAC Glo
TM
 reagent were transferred to a 96-well white 
opaque (Fisher) and the deacetylase activity was measured as luminescence at optimal gain using 
Geniosplus Fluorimeter.  
 Mean signal (Positive control, reaction with HeLa lysates) to background (negative 
control, reaction without HeLa lysates) ratio of a minimum of three independent trials with 
standard errors for each HDAC substrate is shown in Section 2.2.3, Figure 2.6, and Table A.4. 
 
 
2.5.7 ELISA-based HDAC activity assay on secondary antibody coated plates using 
HDAC Glo
TM
 reagent 
2.5.7.1 Binding of primary HDAC antibody  
 
 Secondary antibody coated 96-well opaque plates (Thermo Scientific) were incubated 
with primary HDAC1, HDAC2, HDAC3 or HDAC6 (Sc-11420) antibody (Table 3, 100 µL of 
10µg/mL in 3% BSA and 1X TBST buffer). In the cases of HDAC1 and HDAC2, the plate was 
rocked (3rpm, VWR rocking platform) at room temperature for 1 hour, whereas for HDAC3 and 
HDAC6 the plate was incubated overnight at 4 C without rocking. After binding of the primary 
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antibody to the well, the unbound antibody was removed and the wells were washed with 1X 
TBST buffer as described in section 2.5.5. In case of negative controls, instead of primary 
HDAC antibody, 100 µL of 3% BSA in 1X TBST buffer was incubated.  
 
2.5.7.2 Immunocapture of HDACs 
 
 After the binding of primary antibody to secondary antibody coated wells and washing 
the plate, HeLa lysates (100 µL of 100 µg/mL for HDAC1, HDAC2, and HDAC3 and 1000 
µg/mL for HDAC6, in 0.1 % non-fat dry milk in 1X TBST buffer) were added. To optimize the 
HeLa lysates concentration, we incubated with varying concentrations of HeLa lysates as shown 
in Chapter 2, Section 2.2.3.1, and Figure 2.8. The plate was incubated for 1 hr at 4 C without 
rocking followed by washing the plate with 1X TBST wash buffer (3 times with HDAC1, 2, and 
3, whereas 6 times in the case of HDAC6) and an additional time for 5 min on a rocker, as 
described in Section 2.5.5 The plate was repeatedly tapped onto the filter paper after empting the 
wash buffer to completely dry the wells.  
 
 
2.5.7.3 Incubation of HDAC GloTM reagent  
 
 After affixing the antibody and HDAC isoform, each well was then incubated with 25 µL 
each of the HDAC Glo
TM
 buffer (Promega) and HDAC Glo reagent (Promega) for a 50 µL total 
volume. The HDAC Glo
TM
 reagent was prepared by premixing 1 mL of the HDAC Glo
TM
 
substrate and 1 µL of the HDAC Glo developer and stored in a single use aliquots at -20 C until 
needed. The reaction mixture was incubated for 30-45 min at room temperature and the 
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deacetylase activity was measured as luminescence at optimal gain using a Geniosplus 
Fluorimeter (Tecan). Signal to background ratio was calculated by dividing the signal of positive 
control (reaction with primary HDAC antibody, HeLa lysates, HDAC Glo buffer, and HDAC 
Glo
TM
 reagent) with background signal (negative control with HeLa lysates, HDAC Glo buffer, 
and HDAC Glo reagent minus the primary HDAC antibody in the first step as described in 
Section 2.4.7.1). The mean of a minimum of three independent trials with standard error are 
shown in Section 2.2.3.2, Figure 2.9, Table A.5, A.6, A.7, and A.8. 
2.5.8 ELISA-based HDAC activity assay on high binding polystyrene plates 
2.5.8.1 Binding of primary HDAC antibody 
 High binding polystyrene 96-well white opaque plates purchased from Thermo Scientific 
(catalog 15042) were incubated with primary HDAC1 or HDAC2 antibody (100 µL of 10µg/mL 
in 0.2M carbonate and 0.2M bicarbonate buffer, pH 9.4) or HDAC6 (Sigma, H00010013-M13) 
antibody (100 µL of 2 µg/mL in carbonate and 0.2M bicarbonate buffer, pH 9.4) with rocking 
for 1 hr (3 rpm, VWR rocking platform) at room temperature or overnight at 4 C. In the case of 
HDAC6 antibody, the optimal antibody concentration was determined by varying the antibody 
concentration as shown in Section 2.2.3.1 and Figure 2.10B. Incubation was followed by 
washing away the unbound antibody with 1X TBST wash buffer 3 times and an additional one 
time washing for 5 min with rocking at room temperature, as described in Section 2.5.5. The 
plate was dried by repeatedly tapping on the filter paper after empting the buffer.  The unbound 
regions of the high binding polystyrene wells were blocked with 300µL of 5% non-fat dry milk 
in 1X TBST buffer for 1 hr at room temperature on the rocking platform (3 rpm). Blocking was 
followed by inversion of the plate and washing 3 times with 1X TBST buffer and a final wash 
for 5 min with rocking at room temperature. Negative control was set up by adding 100 µL of 
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0.2M carbonate and bicarbonate buffer, pH 9.4 instead of primary HDAC antibody.  
2.5.8.2 Immunocapture of HDACs 
 Procedure same as in Section 2.5.7.2. In case of HDAC6 antibody, the optimal HeLa 
lysates concentration was determined by varying the lysates concentration as shown in Section 
2.2.3.1 and Figure 2.10A.  
2.5.8.3 Incubation of HDAC GloTM reagent  
 Procedure same as in Section 2.5.7.3. Signal to background ratio was calculated by 
dividing the signal of positive control (reaction with primary HDAC antibody, HeLa lysates, 
HDAC Glo buffer, and HDAC Glo reagent) with background signal (negative control with HeLa 
lysates, HDAC Glo buffer, and HDAC Glo reagent minus the primary HDAC antibody in the 
first step) and the mean of a minimum of three independent trials with standard error are shown 
in Section 2.2.3.2, Figure 2.11, Table A.9, A.10, A.11. 
2.5.9 Small Molecule Inhibitor Screening 
 For isoform selectivity screening and dose dependent inhibition, all the steps were similar 
to the HDAC assay protocols (section 2.3.8.1 for HDAC1, HDAC2, and HDAC6 and 2.3.7.1 in 
the case of HDAC3) up to the immunocapture of HDAC isoform from HeLa lysates. After the 
HDAC proteins were affixed to the respective plates, the inhibitor resuspended in 100% DMSO 
(1 µL) and diluted with the HDAC Glo
TM
 buffer to give a final volume of 25 µL, was added to 
each well and incubated for 15 min at room temperature (a final concentration of 2% DMSO is 
used for all the inhibitor screening). The inhibitor concentration at the pre incubation step was 
two times higher than the final concentration used in Tables A.13-A.23.  
 Later HDAC Glo reagent (25 µL, Promega, prepared as described in Section 2.5.7.3) was 
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added to each well and incubated for an additional 30-45 min at room temperature. The 
deacetylase activity was measured as luminescence using a Geniosplus Fluorimeter (Tecan) at 
optimal gain as described in Section 2.5.7.3 and 2.5.8.3. 
2.5.10 Quantitative analysis 
 For isoform selectivity screening at single concentration, percent deacetylase activity was 
calculated by dividing the signal of reaction containing primary HDAC antibody, HeLa lysates, 
HDAC Glo buffer, HDAC Glo reagent and HDAC inhibitor with the signal of reaction 
containing primary HDAC antibody, HeLa lysates, HDAC Glo buffer, HDAC Glo reagent and 
no HDAC inhibitor followed by  multiplying with 100.  Mean percent deacetylase activity of 
individual HDACs of a minimum of three independent trials with standard error are shown in 
Section 2.2.3.3 and Figure 2.12, and Table A.12. 
 
 For dose dependent inhibition, the luminescence signal of the positive control with or 
without inhibitor (containing HDAC antibody, lysates, HDAC Glo buffer, HDAC Glo reagent) 
was background corrected with the negative control (containing HeLa lysates, HDAC Glo buffer, 
and HDAC Glo reagent minus primary HDAC antibody and without inhibitor). After 
background correction, the percent deacetylase activity at each concentration of inhibitor was 
determined by dividing the signal with inhibitor by the signal without inhibitor and then 
multiplying by 100. The mean percent deacetylase activity of a minimum of three independent 
Trials with standard errors at each inhibitor concentrations are shown in Table A.13, A.14, A.15, 
and, A.16 for SAHA, Table A.17, A.18, and A.19, for apicidin, and Table A.20, A.21, A.22, and 
A.23 for tubastatin. To determine the IC50 values, the percent remaining deacetylase activity at 
each concentration of inhibitor was plotted against the small molecule concentration. The data 
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was fit to a sigmoidal dose-response curve (y=100/(1+(x/m1)
m2
)) using Kaleidograph 4.0 
(Synergy) software, where m1 is the IC50 value in molar units.   
2.5.11 Calculation of Z' factor and percent coefficient of variation (CV)128 
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 σs is the standard deviation of signal (reaction with primary HDAC antibody, HeLa 
lysates, and HDAC substrate) 
 σb is the standard deviation of background (reaction with HeLa lysates and HDAC 
substrate, but without primary HDAC antibody) 
 µs is the mean of signal 
µb is the mean of background 
Z' factor calculation for ELISA-based HDAC1 activity assay using R110-Lys(Ac) substrate, 3 is 
shown in Table A.2.
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  Chapter 3
Identification of Isoform Selective HDAC Inhibitors 
Histone deacetylases are promising drug targets due to their association with various 
diseases (Chapter 1, Section 1.5). HDAC inhibitors are divided into three regions based on their 
interaction with the active site channel of the protein (Chapter 1, Section1.8, and Figure 1.8). 
Over the past few years, the Pflum lab has focused on elucidating the structural requirements for 
potency and selectivity of SAHA, with the emphasis on the hydrophobic carbon linker chain, 
which spans the 11Å hydrophobic channel of the active site of histone deacetylase protein. In 
this pursuit, Pflum lab modified the C2-position
131
 and C3-position
132
 close to the zinc-binding 
moiety, and C6-position
133
 of SAHA close to the capping group with variety of hydrophobic 
substituents (Figure 3.1). Modification at the region close to the hydroxamic acid in the C2 and 
C3 derivatives dramatically reduced the inhibitory activity compared to SAHA, indicating that 
this region of the inhibitor can accommodate limited steric bulk. In contrast, the C6-SAHA 
derivatives exhibited similar potency to the parent SAHA compound. From these results, it is 
evident that derivatization of the linker region close to capping group of SAHA could yield more 
potent compounds than SAHA. In addition, the reported literature shows that alteration of the 
capping group of an HDAC inhibitor with bulky substituents leads to potent and selective HDAC 
ligands.
105,134,135
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Figure 3.1: Chemical representation of SAHA derivatives 
 
3.1 C7-SAHA derivatives 
 Taking the lead from structural requirements studies on SAHA, Pflum lab moved forward 
with the modification of the C7-position of the linker (Figure 3.1), which is closest to the 
capping region of SAHA with hydrophobic and polar substituent for potent and selective SAHA 
derivatives. 
3.1.1 Synthesis of SAHA analogues modified at C7-position 
 Initially, synthesis of C7-SAHA derivatives was performed by a previous Pflum lab 
member, Dr. Anton Bieliauskas, with the attachment of hydrophobic substituent methyl, benzyl, 
and 4-naphthylmethyl groups at the C7-position on the linker region of SAHA.
136
 The HDAC 
inhibitory activity of the synthesized C7-SAHA derivatives was measured using in vitro HDAC 
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Fluor-De-Lys
TM
 fluorometric assay and HeLa lysates by Pflum lab member, Dr. 
S.V.W.Weerasinghe. 
Table 3.1: Inhibitory activities of C7-SAHA 8a-c analogs against whole HeLa lysates taken 
from dissertation of Dr. S.V.W.Weerasinghe.
137
 
Compound R IC50 (nM) 
SAHA H 90±4 
8a Methyl 105±6 
8b Benzyl 109±5 
8c Naphthyl 16±1 
Refer to Table 6 of chapter 4 in the thesis of Dr. Bieliauskas
136
. 
 The HDAC inhibitory activities of C7-methyl 8a and benzyl 8b derivatives were similar 
to SAHA. However, the C7-naphthylmethyl SAHA 8c analogue was six-fold more potent than 
the parent SAHA. The IC50 data confirm the hypothesis that steric bulk on the capping group can 
be accommodated near the rim of the active site channel. In some cases the substituents enhance 
the potency of the molecule compared to the parent HDAC inhibitors, SAHA. To probe the 
effect of bulky groups on the linker region, we further altered the C7-position with large 
hydrophobic groups, such as 4-biphenyl, 9-anthracylmethyl, 9-(1,2,3,4-tetrahydroanthracenyl). 
Apart from these, a polar group like 4-pyridyl was also appended at the C7-position to probe the 
hydrophilic interactions with the solvent exposed region of the HDAC active site. C7-
anthracenyl 8e and C7-tetrahydroanthracenyl  8f were synthesized by Dr. Satish Garre, whereas 
C7-pyridyl 8g was synthesized by Dr. Sun E Choi.
138
 The full characterization and synthesis of 
C7-biphenyl SAHA 8d will be discussed here.  
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 Synthesis of C7-biphenyl SAHA 8d began with nucleophilic substitution of dibenzyl 
malonate with 6-bromo methyl hexanoate 4 to produce dibenzyl malonate ester 5, which on 
reaction with alkyl halide (4-biphenyl bromide) furnished the respective alkylated malonate ester 
6d. Deprotection followed by decarboxylation of the alkylated ester gave the mono carboxylic 
acid derivative, which coupled with aniline afforded ester anilides 7d. Coupling of the ester 
moieties with hydroxylamine hydrochloride furnished the final hydroxamic acid 8d (Scheme 3.1) 
 
Figure 3.2: Synthetic scheme of C7-SAHA 8d derivatives through malonate ester. 
  
Dose-dependent inhibition of the newly synthesized C7-SAHA derivatives against HeLa 
cell extract was measured using commercially available HDAC Fluor-De-Lys
TM
 fluorometric kit 
(Enzo Life Sciences). The HDAC inhibitory activity of the C7-biphenyl methyl derivative 8d is 
fully reported here, whereas the activity of remaining C7-SAHA (8e-f) derivatives was 
performed by Dr. Sun E Choi.
138
 From the IC50 values of C7-SAHA compounds represented in 
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Table 3.1 and Table 3.2, the biphenyl analogue 8d was the most potent among the C7-series, 
which is around 22-fold more potent than parent SAHA compound. The bulky hydrophobic 
tetrahydro anthracenyl 8f derivative showed potency comparable to SAHA or the smallest 
methyl variant 8a. These results confirm that the solvent exposed region of the active site can 
accommodate sterically bulky substituents without the loss of potency. However, the polar 
variant among this series, pyridyl derivative 8g, showed least potency among all the other 
compounds, suggesting that the rim of the active site channel can accommodate bulky groups but 
not polar residues, consistent with the previous work on the capping group 
96,139-141
.  
Table 3.2: IC50 values of remaining C7-SAHA derivative 8d-8g 
Compound R IC50 (nM) 
SAHA H 90±4
a
 
8d Biphenyl 4.0±0.7
a 
8e Anthracyl 20±1
b 
8f Tetrahydroanthracyl 102±30
b 
8g 4-Pyridyl 450±35
b 
a. See Table B.1 b. See Table 3.1.4 in the thesis of Dr. Sun E Choi
138
. 
3.1.2 Isoform selectivity screening of C7-SAHA analogs against recombinant HDAC 
isoforms 
 
 In order to probe the structural requirements of SAHA at the capping group on isoform 
selectivity, the inhibitory activities of the C7-SAHA derivatives against recombinant HDAC 
isoforms was assessed by Dr. Sun E Choi. Initial experiments involved testing the potency of the 
individual C7-SAHA derivatives at single concentration near to the IC50 values against the 
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recombinant HDAC1, 3, and 6 from baclovirus overexpression using the commercially available 
HDAC Fluor-De-Lys
TM
 assay kit (Enzo Life Sciences) (Figure 3.2).
138
  
 
Figure 3.3: Isoform selectivity screening of C7-SAHA library against recombinant HDAC 
isoforms. C7-methyl 8a, benzyl 8b, tetrahydroanthracenyl 8f, and biphenyl 8d were screened at 
100 nM with recombinant HDAC1, HDAC3, and HDAC6. C7-pyridyl 8g and anthracenyl 8e at 
500 nM, and naphthyl 8c variant at 1 nM. The mean percent of remaining deacetylase activity of 
HDAC isoform of minimum three independent trials with standard errors was plotted. 
Reproduced from Dr. Sun Choi thesis.
138
 
 
 C7-methyl SAHA 8a, the smallest derivative, C7-benzyl SAHA 8b, C7-
tetrahydroanthracenyl derivative, the largest analog, did not show any isoform selectivity at a 
single concentration similar to pan-inhibitor SAHA. The biphenyl variant 8d, the most potent 
analogue against whole HeLa lysates, showed the least isoform selectivity at a concentration 
inhibiting the three HDAC isoforms with equal potency. C7-naphthyl variant 8c showed some 
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HDAC3 selectivity over HDAC1 and HDAC6 isoforms. C7-pyridyl 8g and C7-anthracenyl 
derivatives 8e showed dual HDAC1/HDAC6 isoform selectivity at 500 nM and 1 nM 
respectively. 
 With the isoform selectivity data at a single concentration, the dose-dependent inhibition 
of the most prominent derivative, C7-9-anthracenyl SAHA 8e was determined with individual 
recombinant HDAC isoforms using the commercially available Fluor-De-Lys
TM
 in vitro assay. 
The C7-anthracenyl analogue 8e showed modest dual HDAC inhibitor property from the 
obtained IC50 values. It was found to be 4-fold HDAC1 selective inhibitor over HDAC3 isoform 
and 3-fold more potent for HDAC6 over HDAC3 isoform (Dr. Sun Choi's thesis, data not shown 
here). The single concentration selectivity screen and dose-dependent inhibition results suggests 
that bulky hydrophobic substituent like anthracene on the linker impart modest selectivity along 
with potency.  
3.1.3 Isoform selectivity screening of C7-SAHA analogs against human HDAC isoforms 
 With the established, inexpensive, ELISA-based HDAC activity assay (Chapter 2, 
Section 2.2.3, Figure 2.5), our next goal was to assess the isoform selectivity of C7-SAHA 
derivatives against mammalian cell-derived HDAC proteins. The individual human HDAC 
isoforms were immunoprecipitated on 96-well high binding polystyrene plates (for HDAC1, 2, 
and 3) or secondary antibody coated 96-well plates (in case of HDAC3). With the help of 
developed HDAC activity assay the potency of the C7-SAHA derivatives, except C7-pyridyl 
analogue, was tested at single concentration (Figure 3.3).  
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Figure 3.4: Isoform selectivity screening of C7-SAHA library against human HDAC 
proteins. Potency of C7-SAHA analogs at single concentration with HDAC1, HDAC2, HDAC3, 
and HDAC6 isoforms. C7-benzyl 8b and tetrahydro anthracenyl 8f derivatives were screened at 
a single concentration of 50 nM. C7-Naphthyl 8c, biphenyl 8d and anthracenyl 8e analogues 
were screened at 20 nM, whereas methyl variant 8a was screened at 100 nM. Mean percent of 
signal (deacetylase activity with inhibitor) to background (deacetylase activity without inhibitor) 
of minimum three independent trials with standard errors was plotted. 
 
 Among the C7-SAHA analogs, benzyl 8b, naphthyl 8c, and biphenyl 8d variants showed 
the least selectivity among the human HDAC isoforms tested. The smallest methyl group on C7 
position also showed insignificant selectivity for the individual HDAC isoforms. In contrast, 
analogs with the large substituents, anthracenyl 8e and tetrahydroanthracenyl 8f displayed 
selectivity for HDAC6 over the class I HDAC isoforms (Table B.2 to B.7).  
 The selectivity profile of the anthracenyl derivative 8e was further assessed through 
measurement of IC50 values against individual mammalian HDAC isoforms using the ELISA-
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based HDAC activity assay. The C7-9-anthracenyl SAHA 8e analog exhibited 5-fold selectivity 
for HDAC6 over HDAC1 and 2 isoforms, whereas around 10-fold selectivity for HDAC6 over 
HDAC3 (Table 3.3). The inhibitory and selectivity profiles of C7-SAHA small molecule library 
strongly suggests that the HDAC active site can accommodate bulky substituent at the solvent 
exposed region to generate potent compounds than SAHA (Table 3.1, 3.2), and bulky 
substituents like anthracene can impart some selectivity among HDAC isoforms. (Figure 3.4, 
Table B.8 to B.11). 
 
Figure 3.5: Dose-response curves of C7-9-anthracenyl SAHA analogue 8e with individual 
human HDAC1, HDAC2, HDAC3, and HDAC6 isoforms with error bars depicting the standard 
error of more than three independent trials. In few cases, the error bars is smaller than the marker 
size. IC50 values were determined by fitting the data to a sigmoidal curve using Kaleidograph 4.0 
(Synergy Software) as shown in Table 3.3 and Table B.8-B.11 
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Table 3.3: IC50 values of SAHA and C7-9-anthracenyl derivative 8e with individual human 
HDAC isoforms 
 
Compound 
IC50(nM) 
HDAC1 HDAC2 HDAC3 HDAC6 
SAHA
a
 33±0.14 96±1.0 20±0.3 33±2.7 
8e 54±4.0 64±8.0 119±19 12±3.0 
a. See Chapter 2, Table 2.2, Table A.13-A.16. 
  
3.2 C2-SAHA derivatives 
 
  
HDAC inhibitor SAHA is divided into three regions, metal-binding moiety, linker region and 
capping group (Chapter 1, Section 1.7, Figure 7). To study the role of hydrophobic substituents 
on the linker region, which is in close proximity to the metal-binding moiety of SAHA, Dr. 
Anton Bieliauskas synthesized a library of C2-SAHA derivatives. 
131
 The inhibitory activity of 
the individual derivatives was tested against whole HeLa nuclear extract using the in vitro  
fluorometric Fluor-De-Lys
TM
 assay by Dr. Sujith Weerasinghe, a previous Pflum lab member.
131
 
The published structural-activity relationship of these analogues against variety of HDAC 
isoforms in whole HeLa lysates is shown in Table 3.4. 
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Table 3.4: HDAC inhibition of C2-SAHA small molecule library against HeLa cell 
extracts.
131,136
 
Compound R IC50 (µM)
 
SAHA H 0.09±0.004 
MS-275 H 3.2±(0.1) 
9a Methyl 134±6 
9b Ethyl 449±17 
9c n-Propyl 154±7 
9d n-Butyl 72±6 
9e Allyl 144±9 
9f Propargyl 87±5 
9g Benzyl 226±11 
9h n-Pentyl 40±3
a 
9i n-Hexyl 60±5
a 
a- See table in Anton's thesis (referr) 
 The C2-SAHA compounds were inhibitors with potency in high micromolar range. The 
most potent among this library is C2-n-pentyl 9h with an IC50 of 40µM, whereas the least potent 
is the C2-ethyl SAHA 9b variant with an IC50 of 449µM. The biological analysis of the C2-
library against HeLa lysates demonstrated that any hydrophobic substituents close to the 
hydroxamic acid reduces the potency of SAHA. We had not screened C2-SAHA small molecule 
library for isoform selectivity owing to the potency of the compounds in sub micromolar range 
and the high cost of the reagents used in the assay. With the optimized inexpensive ELISA-based 
HDAC activity assay (Chapter 2, Section 2.2.3), the isoform selectivity screening using the 
optimized ELISA-based HDAC activity assay was performed. 
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3.2.1 Isoform selectivity screening of C2-SAHA analogs against human HDAC isoforms 
 With establishment of the ELISA-based HDAC activity assay for selectivity screening in 
a cost-effective manner, the structural-activity relationship of the C2-SAHA small molecule 
library against individual human HDAC proteins was probed. Individual human isoforms were 
immunoprecipitated on 96-well high binding polystyrene plates (for HDAC1, 2, and 3) or 
secondary antibody coated 96-well plates (in case of HDAC3), with subsequent use in the 
HDAC activity assay (Chapter 2, Figure 2.5). The potencies of the C2-SAHA derivatives were 
tested at a single concentration of either 1µM or 5µM (Figure 3.5). All the C2-SAHA derivatives 
displayed some selectivity against the HDAC6 isoform over HDAC1, HDAC2, and HDAC3. 
Among them, C2-n-pentyl 9h, C2-n-hexyl 9i, and C2-benzyl SAHA analogs 9g showed the 
highest HDAC6 selectivity at 5µM single concentration. In contrast, the C2-methyl SAHA 
analog was the least selective derivative with selectivity comparable to pan inhibitor SAHA.   
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Figure 3.6: Isoform selectivity screening of the C2-SAHA library against human HDAC 
proteins. The potencies of C2-SAHA analogues with individual immunoprecipitated human 
HDAC1, 2, 3 and 6 isoforms at single concentration of 5µM for 9a-i, and 10µM for 9d. Mean 
percent of signal (deacetylase activity with inhibitor) to background (deacetylase activity without 
inhibitor) of minimum three independent trials with standard errors was plotted (Table B.12 to 
Table B.20). 
 
 To further evaluate the selectivity observed in the initial screen, dose-dependent 
inhibition of C2-benzyl 9g, C2-n-pentyl 9h, and C2-n-hexyl 9i was determined (Figure 3.7, 
Figure B.3, and Figure B.4, respectively). The C2-n-pentyl analog 9h displayed 30-fold 
selectivity for HDAC6 over Class I HDAC1, HDAC2, and HDAC3, whereas C2-n-hexyl 9i 
showed 50-fold selectivity for HDAC6 over HDAC1, HDAC2, and HDAC3 isoforms. Among 
the C2-SAHA derivatives, C2-benzyl SAHA 9g showed the best selectivity of 87-fold to 
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HDAC6 over HDAC1, HDAC2, and HDAC3 isoform, which is similar to the HDAC6 selectivity 
of known HDAC inhibitor tubastatin (87-fold) against mammalian HDAC6 isoform
35
 (discussed 
in Chapter 2, Section 2.2.3.3, Figure 2.15) tested with our assay. 
 
Figure 3.7: Dose dependent curves of C2-Benzyl SAHA derivative 9g with individual HDAC1, 
HDAC2, HDAC3, and HDAC6 isoforms with error bars depicting the standard error of more 
than three independent trials. Mammalian individual HDAC isoforms are immunoprecipitated 
from HeLa cell lysates using HDAC activity assay and the catalytic activity of each HDAC 
isoforms was tested in the absence and presence of varying concentrations of 9g. IC50 values 
were determined by fitting data to a sigmoidal curve using Kaleidograph 4.0 (Synergy Software). 
In few cases, the error bar is smaller than marker size. Dose dependent curves for 9h and 9i are 
shown in Figure B.3 and B.4, respectively. 
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Table 3.5: IC50 values (µM) of C2-benzyl (9g), C2-n-pentyl (9h), and C2-n-hexyl (9i) SAHA 
variants with HDAC1, HDAC2, HDAC3 and HDAC6 
 
 Data in appendix B, Table B.21 to B.32 
 In conclusion, the pilot screening of synthesized SAHA derivatives using HDAC activity 
assay identified an HDAC6-selective C2-benzyl SAHA analog, 9g. The selectivity profile of all 
the analogs screened suggest that derivatization at the linker region of SAHA closer to the metal 
binding moiety furnish selective HDAC6 inhibitors.  
3.2.2 Docking studies of C2-benzyl SAHA  
 Encouraged by the HDAC6 isoform selectivity of C2-benzyl SAHA analogue, Ahmed 
Negmeldin, graduate student in Pflum lab performed docking analysis using AutoDock 4.2 
program.
142
 Initially SAHA, a known HDAC inhibitor was docked into HDAC2 (HDAC2 crystal 
structure was downloaded from the protein data bank, pdb ID: 3MAX) and HDAC6 structure 
(HDAC6 homology
143
) and the binding interactions with the catalytic pocket were studied (data 
not shown).  
With the successful docking of SAHA into the HDAC2 and HDAC6 structures, 
molecular binding interactions of the two enantiomers of the HDAC6 selective analogue, C2-
benzyl SAHA 9g with HDAC2 and HDAC6 was investigated (Both the enantiomers gave similar 
relative energies and binding interactions, hence only docking simulations of S enantiomer is 
Compound IC50 values (µM) 
HDAC1 HDAC2 HDAC3 HDAC6 
9g 131±5.6 151±12 110±14 1.3±0.1 
9h 41±2.5 62±4.0 31±1.4 0.98±0.14 
9i 109±9 155±3 55±8 1.1±0.1 
83 
 
 
represented here after). Docking studies of S enantiomer of compound 9g with HDAC6 shows 
that it adopts optimal binding confirmation in the active site channel through formation of three 
H-bonds with His130, His131, and Tyr302 similar to SAHA (Figure 3.8A) which are important 
to stabilize the chelation of hydroxamic acid moiety with zinc atom. The wider catalytic pocket 
and favorable hydrophobic interaction between active site residue Phe140 and the benzyl 
substituent of the analog explain the potency observed for HDAC6 over other HDAC isoforms 
further substantiated from the overlay docking analysis of SAHA with (S)-C2-benzyl SAHA 
variant (Figure 3.8B).  
 Figure 3.8: Computational studies of C2-Benzyl SAHA with HDAC6. A. In silico docking 
studies of S-C2- enzyl SAHA analog 9g (red) with catalytic pocket of HDAC6 (green). B. 
docking simulation of S-C2-Benzyl SAHA analog 9g (red) and SAHA (yellow) with HDAC6 
homology model. 
 
To investigate the potency compound 9g against class I HDACs, docking analysis of the 
S enantiomer was performed using crystal structure of HDAC2 protein. Weak H-bonding 
interactions was observed from the elongated bond distances of His 145 with OH group (5.2Å), 
His 146 with NH group (3.6Å), and Tyr 308 with carbonyl group (2.9Å) of hydroxylamine of 
A B
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compound 9g and the metal chelation was also weak with longer bond distances than the pan-
inhibitor SAHA (Figure 3.9A). One possibility accounts for the decreased binding affinity is the 
bulky hydrophobic benzyl substituent cannot go through the narrow catalytic active channel of 
HDAC2 which is confirmed from the super imposable docking simulation of S enantiomer of 
compound 9g with SAHA (Figure 3.9B). 
Docking studies combined with in vitro selectivity screening with individual HDAC isoforms 
unambiguously demonstrate C2-benzyl SAHA 9g compound to be more active against HDAC6 
protein over class I HDAC2 isoform. 
 
Figure 3.9: Docking studies of C2-Benzyl SAHA with HDAC2. A. In silico docking studies of 
S-C2- enzyl SAHA analog 9g (red) with catalytic pocket of HDAC2 (green). B. Overlay image 
of S-C2-Benzyl SAHA analog 9g (red) and SAHA (yellow) with HDAC2 (green) structure. 
 
 
A B
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3.3 C3-Ethyl SAHA derivative 
 
 
 
 Dr. Sun E Choi synthesized the C3-SAHA small molecule library to elucidate the 
structural requirements for potency and selectivity by attaching hydrophobic substituents at the 
C3-position of the linker. 
132
 The biological inhibitory activity of the C3-SAHA compounds was 
measured using in-vitro Fluor-De-Lys
TM
 HDAC fluorescence activity kit using HeLa lysates. 
The data suggests the derivatives to be less potent compared to SAHA, consistent with the 
previous results with C2-SAHA derivatives where minimum steric bulk can be accommodated at 
the linker region close to the hydroxamic acid moiety. The isoform selectivity screening of C3-
SAHA derivatives at against Class I HDAC1, HDAC3 isoforms and Class II HDAC6 
recombinant protein was performed using HDAC Fluor-De-Lys
TM
 activity kit (Enzo Life 
Sciences) by Dr. Sun Choi. Among all the variants, C3-ethyl SAHA analogue 10 displayed some 
selectivity among the HDAC isoforms tested. The IC50 value against HDAC6, HDAC3, and 
HDAC1 were determined to be 8µM, 97µM, and 22µM, respectively. These results indicate 12 -
fold HDAC6 selectivity over HDAC3 and 3-fold selectivity for HDAC6 over HDAC1 isoform 
(Table 3.6).  
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Table 3.6: IC50 values of SAHA and C3-ethyl SAHA 10 against individual recombinant 
HDAC isoforms.
132
 
Compound IC50(µM) 
HDAC1 HDAC3 HDAC6 
SAHA 0.096±0.016 0.146±0.012 0.074±.009 
10 22±2 97±6 8.0±1 
Data obtained from dissertation of Dr. Sun Choi.
138
  
 To further test the reproducibility and reliability of the developed ELISA-based HDAC 
activity assay, we determined the IC50 values of C3-ethyl SAHA 10 against individual human 
HDAC1, HDAC2, HDAC3, and HDAC6 isoforms using the optimized high throughput assay. 
The selectivity data against individual human HDAC isoforms (Table 3.7) is consistent with that 
obtained against recombinant proteins (Table 3.6). The C3-ethyl SAHA derivative displayed 
around 10-fold HDAC6 selectivity over class I HDAC1, HDAC2, and HDAC3 isoforms. The 
selectivity data is in accordance with the original hypothesis that the modification of the region 
close to hydroxamic acid generate less potent compounds, but the selectivity among the HDAC 
isoforms is increased. 
Table 3.7: IC50 Values of SAHA and C3-ethyl SAHA 3 against individual mammalian 
HDAC isoforms using ELISA-based HDAC activity assay 
Compound IC50(µM) 
 HDAC1 HDAC2 HDAC3 HDAC6 
SAHA 0.033±0.0014 0.096±0.001 0.02±0.0003 0.033±.0027 
10 9.6±0.7 13±0.7 10±1.0 1.0±0.3 
Data is shown in Appendix B, Figure B.4 and Table B.33 to B.36. 
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3.4 Discussion of the observed results 
3.4.1 Discussion of C7-SAHA activity profile 
 C7-SAHA derivatives displayed sub and low nanomolar inhibitory activities with few 
analogs being more potent than parent compound SAHA (90nM). With an increase in the size of 
the substituent at the C7-position, the potency of the small molecule increased, with the activity 
of the smallest methyl variant 8a similar to SAHA (Table 3.1). The biphenyl variant 8d was 
around 20-fold more potent than SAHA against HeLa lysates (Table 3.2 ), but was among the 
least selective analog against individual HDAC isoforms at single concentration. The least potent 
of the C7-library is the pyridyl derivative 1g with 5-fold less potency than SAHA (Table 3.2), 
which indicate that the solvent-exposed region of the active site cannot accommodate polar 
residues. Isoform selectivity screening of the C7-SAHA library at a single concentration with 
recombinant and human individual HDAC proteins indicated that the selectivity of modified 
analogs was comparable to pan inhibitor SAHA (Figure 3.2, Figure 3.3). The anthracenyl variant 
1e was the most HDAC6 selective compound and demonstrated five-fold selectivity for HDAC6  
with an IC50 value of 12nM than HDAC1 with IC50 value of 54nM and HDAC2 with an IC50 
value of 64nM, whereas 10-fold more HDAC6 inhibitory activity over HDAC3 isoform with an 
IC50 value of 119nM (Table 3.3). The inhibitory and selectivity profiles of C7-SAHA small 
molecule library strongly suggests that the HDAC active site can accommodate bulky substituent 
at the solvent exposed region to generate potent HDAC inhibitors than parent compound, SAHA, 
and bulky substituents like anthracene impart some selectivity to HDAC inhibitors among 
HDAC isoforms. 
88 
 
 
3.4.2 Discussion of selectivity trend among C2-SAHA derivatives 
 The inhibitory activities of the C2-SAHA library (Table 3.4) with HeLa nuclear extract 
displayed micromolar potency compared to the nanomolar potency of SAHA.  The size of the 
hydrophobic substitution on the C2-position has limited effect on the inhibitory activity with n-
pentyl 9h analogue, the most potent and methyl variant 9a the least potent of the series. 
Surprisingly, the isoform selectivity screening of the C2-library at single concentration of either 
10µM or 5µM using the ELISA-based HDAC activity assay revealed the compounds to be 
selective for HDAC6. The smallest methyl variant 9a showed the least selectivity whereas the 
largest n-pentyl 9h, n-hexyl 9i, and benzyl 9g derivatives were the most selective HDAC6 
ligands among the C2- library. The dose-dependent inhibition results of these selective inhibitors 
with individual HDAC isoforms identified a 87-fold HDAC6 selective, C2-benzyl SAHA 
derivative 9g, which is more selective than the known HDAC6 selective compound, tubastatin 
with 87-fold selectivity for HDAC6 over class I HDAC isoforms (Table 3.5). From the 
selectivity screening and docking studies results, it is confirmed that bulky hydrophobic 
substituents on C2-position are more tolerable in the HDAC6 active site 11Å channel due to the 
wider catalytic pocket and favorable binding interactions. 
3.4.3 Discussion of the structural studies of HDACi 
 Structure of HDAC inhibitor is divided into three specific functional region depending on 
its interaction with the active site of the HDAC protein. The linker region of the HDAC inhibitor 
interacts with the highly conserved hydrophobic active site 11Å channel. Several studies were 
performed by modification of the hydrophobic linker region. For example, nanomolar potency 
was observed for HDAC inhibitors like MS-275 (Chapter 1.7, Figure 1.7), panobinostat (Figure 
3.7), and belinostat (Figure 3.7) with an intra-linker aryl group. A tyrosine-based hydroxamic 
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acid with tyrosine linker displayed HDAC8 selectivity (Figure 3.7).
144
 LMK235 with a novel 
alkoxyamide linker displayed equipotent HDAC inhibition with voronistat and isoform 
selectivity for HDAC4 and HDAC5 isoforms (Figure 3.7).
145
 Structural studies on C2 and C3-
position of the linker region of SAHA with additional hydrophobic substituents displayed 
micromolar potency compared to the nanomolar potency of SAHA (Figure 3.1). Comparison of 
the biological inhibitory activity data of C2-SAHA and C3-SAHA suggests that the IC50 values 
diminish with the substitution closer to the hydroxamic acid of SAHA. For instance, C2-ethyl 
SAHA (449µM) is 14-fold less potent than the respective C3-ethyl SAHA (32µM). However, the 
SAHA derivatives demonstrated some selectivity for class II HDAC6 isoform over class I 
HDAC isoforms, with highest HDAC6 selective for C2-benzyl SAHA. Biological analysis of the 
C2-SAHA and C3-SAHA small molecule library indicates that the active site region close to 
hydroxamic acid of class I HDACs has limited flexibility for hydrophobic groups, whereas the 
wider catalytic pocket of HDAC6 active site can accommodate bulky moieties to yield selective 
and potent HDAC inhibitors. Capping group has been widely modified to yield potent and 
specific HDAC inhibitors. Alteration of the C6 and C7-position of the SAHA linker furnished 
potent HDAC inhibitors like C7-biphenyl derivative, which is 5-fold more potent than SAHA. 
However, the selectivity of the C6 and C7-derivatives was similar or little higher than the pan 
HDAC inhibitor SAHA. From the SAR studies of the linker region of SAHA, we conclude that 
modification at the region close to hydroxamic acid leads HDAC6 selective inhibitors with 
decreased potency, whereas alteration of the linker region close to the capping group yield highly 
active HDAC ligands.  
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Figure 3.10: Chemical representation of few isoform selective HDAC inhibitors 
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3.5 Experimental methods 
3.5.1 Reagents 
 Reagents were generally purchased from Fisher Scientific, Acros Organics or Sigma 
Aldrich unless otherwise noted. Iron-free reactions were performed using glassware soaked in a 
6M aqueous HCl bath overnight. Iron-free silica gel was prepared by washing with 6M aqueous 
HCl until colorless and subsequent washing with distilled water, followed by drying under air 
pressure overnight. Dry THF was obtained using THF drying solvent purifier. Thin layer 
chromatography and flash chromatography were carried out with 6 Å, 25 μm Partisil® K6F 
fluorescent indicator plates (Fisher) and 60Å, 230-400 mesh silica gel (EMD), respectively. 
Bovine serum albumin was purchased from Jackson immunoresearch. Non-fat dried milk was 
purchased from the Biorad. Primary HDAC1 (H3284), HDAC2 (H3159), HDAC3 (H3034), 
HDAC6 (SAB1404771) were purchased from Sigma Aldrich as shown in Chapter 2, Table 2.2. 
 
3.5.2 General Equipment 
 Standard equipment include Varian Unity 300MHz, Varian L900 or Varian 500MHz 
instruments housed in the Lumigen instrumentation center in the department of chemistry were 
used to take NMR spectra. LRMS and HRMS spectra were recorded using a Waters LCT 
Premier XE ESI-LC-MS TOF or a Waters GCT EI-TOF in the Lumigen instrumentation facility 
in the department of chemistry. IR spectra were taken on Jasco FT/IR-4100. Standard 
biochemical equipment includes centrifuges (Eppendorf models 5415D and 5810R), bacterial 
incubator/shaker (New Brunswick Scientific C25 Incubator Shaker Classic Series), a Tecan 
GENios Plus spectrophotometer, a VWR rocking platform, and a Barnstead Thermolyne 
Labquake shaker rotisserie. 
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3.5.3 Experimental procedure for Scheme 3.1 
 
 
 
 
Preparation of 1,1-dibenzyl 6-methyl hexane-1,1,6-tricarboxylate (5). To sodium hydride 
(0.34 g, 14.3 mmol) in dry THF (20 mL), dibenzyl malonate (3.5 g, 12.4 mmol) was added 
slowly followed by addition of 6-bromo-hexanoate 4 (2.0 g, 9.6 mmol). The reaction mixture 
was refluxed for 12 hours and filtered over celite. The resulting solution was then evaporated in 
vacuo and residue was purified by flash column chromatography (5 % EtOAc in Hexane) on 
silica gel to afford the desired compound 5 (2.2 g, 60% yield) 
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Preparation of 6,6-dibenzyl 1-methyl 7-(biphenyl-4-yl)heptanes-1,6,6-tricarboxylate (6d). 
To sodium hydride (0.087 g, 3.60 mmol) in dry THF (20 mL), ester 5 (1 g, 2.4  mmol) dissolved 
in THF (5 mL) was added slowly, followed by the addition of 4-(bromomethyl) biphenyl (0.890 
g, 3.6 mmol) dissolved in THF (5 mL). The reaction mixture was refluxed for 2-3 hours and then 
quenched with water (40 mL) and ether (50 mL). The organic layer was separated and the 
aqueous layer was extracted twice with ether (20 mL). The combined organic layers were dried 
over MgSO4 and evaporated in vacuo. The residue was purified by flash column chromatography 
(40% CH2Cl2 in Hexane containing 0.1% MeOH) on silica gel to afford the desired compound 
6d as white solid (778 mg, 55% yield); 
1
H NMR (δ, ppm, CDCl3): δ, 7.25-7.60 (16H, m), 7.0 
(2H, m), 5.14 (4H, s), 3.65 (3H, s), 3.25 (2H, s), 2.23 (2H, s), 1.92 (2H, m), 1.48 (2H, m), 1.25 
(4H,m); 
1
C NMR (δ, ppm, CDCl3) 174.2 (3 C=O), 141.6, 140, 134.8, 134.6, 130.1, 130, 129.4, 
128.6, 128.1, 127.6, 127.2, 127, 66.5, 58.4, 52.9, 38, 34, 32, 28, 25, 22; IR (neat, cm
-1
): 3005, 
2948, 1712, 1420, 1360, 1219, 758, 700; MS(ESI) found (M+H)
+
 579.37; (M+Li)
+
 585.36; 
(M+Na)
+
 601.35; calc. for C37H38O6, 579.89 (M+H)
+
, 585.65 (M+Li)
+
, 601.87, (M+Na)
+ 
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Methyl 7-(biphenyl-4-ylmethyl)-8-oxo-8-(phenylamino) octanoate (7d). To compound 6d 
(0.76 g, 1.3 mmol) dissolved in 4:1 methanol and ethyl acetate (20 mL), Pd(OH2)/C (0.074 g, 
0.52 mmol) was added. The reaction mixture was purged three times with argon and vacuum, 
followed by vacuum purging three times with hydrogen through a hydrogen-filled balloon.  Later 
the mixture was stirred at room temperature under hydrogen pressure. After 3 hours, the resulting 
mixture was filtered over celite and the filtrate was evaporated under reduced pressure. The 
resulting crude dicarboxylic acid gummy liquid was used in the next reaction without any 
purification. 
The crude dicarboxylic acid derivative dissolved in ethyl acetate (20 mL) was heated to 
reflux. After 24 hours, the solution was evaporated under reduced pressure. The resulting crude 
mono carboxylic acid compound was used for next reaction without any purification. 
To the crude solution of mono carboxylic acid derivative in acetonitrile (20 mL), TBTU 
(0.81 g, 2.50 mmol), aniline (0.23 g, 2.50 mmol) and diisopropylethylamine (0.43 g, 3.30 mmol) 
were added. The reaction mixture was stirred for 12 hours at room temperature and quenched 
with saturated aqueous NaHCO3 solution (20 mL). The aqueous layer was extracted three times 
with ethyl acetate (20mL). The combined organic layers were dried over MgSO4 and evaporated 
in vacuo. The residue was purified by flash column chromatography (10% ethyl acetate-hexane) 
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on silica gel to afford the desired compound 7d as an oil (0.4 g, 70% yield); 
1
H NMR (δ, ppm, 
DMSO-d6): δ,=9.8 ( H, s,  H), 7.2-7.65 (14H, m), 3.53 (3H, s), 2.85 (1H, m), 2.69 (2H, m), , 
2.23 (2H, t), 1.47 (4H, m), 1.24 (4 H, m); 
13
C NMR (δ, ppm, DMSO-d6): 174 (2), 140, 139.9, 
139.7, 130 (2C), 129.6 (2C), 129.3, 127.9 (2C), 123.8, 120, 51, 49, 40.4, 38.6, 33.9, 32.5, 29.9, 
26.5, 24.5; IR (neat): 3005, 2936 1712, 1360, 1220, 761 cm
-1
.  ESI-MS: found 430.25 (M+H)
+
, 
436.24 (M+Li)
+
, 452.20 (M+Na)
+
, 468.17 (M+K)
+
. calc. C28H31NO3 430.56 (M+H)
+
, 436.17 
(M+Li)
+
, 452.54 (M+Na)+, 468.52 (M+K)
+
.
 
 
 
 
2-(biphenyl-4-ylmethyl)-N
8
-hydroxy-N
1
-phenyloctanediamide (8d). To a cooled solution (ice-
cooled) of hydroxylamine hydrochloride (0.53 g, 7.6 mol) in methanol (9 mL), KOH pellets 
(0.86 g, 15.27 mol) were added one by one at 0 C for 20 min with stirring. Then compound 7d 
(0.33 g, 0.76 mol) dissolved in methanol (3 mL) was added drop wise at 0º C. The reaction 
mixture was warmed to room temperature. After stirring for 12 hr, the reaction mixture was 
quenched with one drop of distilled water and neutralized with conc. HCl until the pH was 6. 
The aqueous layer was extracted twice with EtOAc (20mL). The combined organic layer were 
dried over MgSO4, evaporated in vacuo, and purified by flash chromatography (2% MeOH in 
CH2Cl2) to afford the desired final compound 8d as white solid (0.17 g, 52% yield). All the 
glassware used in this reaction was acid-washed (Iron-free). 
1
H NMR (δ, ppm, D4-MeOH): 
δ,=7.20-7.60 (13H, m), 7.12(1H, m), 2.97(1H, m), 2.80(1H, m), 2.73(1H, m), 2.06(2H, t, 
J=7.2Hz), 1.63(4H, m), 1.37(4H, m); 
13C  MR(δ, ppm, CDCl3): δ,= 74, 69,  4 ,  39.9,  39.7, 
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138.5 (2C), 130 (2C), 129.6, 129.5, 127.8, 127.2, 123.8, 120, 49, 40.7 (2C), 34, 30, 28, 26; IR 
(neat, cm
-1
): 3370, 2945, 2830, 1707, 1024, 670; HRMS (EI-TOF, m/z): found [M+H]
+
 431.23. 
calc. for C27H31N2O3, 431.23(M+H)
+
. 
 
3.5.4 HDAC in-vitro fluorometric assay 
 HDAC Fluor-De-Lys
TM
 activity assay kit (Enzo Life-Sciences) was employed to measure 
the IC50 value of C7-biphenyl SAHA derivative 8d. HeLa nuclear extract (4 µg of total protein) 
taken in a 1.5 mL eppendorf tube was incubated with or without the small molecule at the final 
volume of 25 µL in HDAC assay buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7mM KCl, 1 
mM MgCl2)  with shaking at 30 C for 30 minutes. Two-fold serial dilution of C7-4-
biphenylmethyl SAHA between 50 nM and 0.78nM final concentration was used in the assay. 
The pre incubation step with HeLa lysates contains 2X the final concentration of small molecule 
(concentrations shown in Table B.1 to B.36). After 30 minute incubation, 25 µL of HDAC Fluor-
De-Lys
TM
 substrate (100 µM final concentration) was added to each reaction and incubated for 
an additional 45 minutes at 30 C with shaking. To the wells of 96-well black opaque plate 
(Fisher), HDAC-Fluor-De-Lys
TM
 developer (2.5µL of 20X diluted to 50µL in HDAC assay 
buffer) was added. The reaction with substrate was added to the wells containing HDAC-Fluor-
De-Lys
TM
 developer and incubated for 5 minutes in dark. All the reactions without small 
molecule contained the same volume of DMSO at a concentration of 2% in the final volume. The 
remaining deacetylase activity was measured as fluorescence using Geniosplus Fluorimeter 
(Tecan) with excitation at 360 nm and emission at 465 nm. The reaction containing HeLa 
lysates, HDAC-Fluor-De-Lys
TM 
substrate and developer with or without inhibitor was 
background corrected with reaction containing HDAC-Fluor-De-Lys
TM 
substrate and developer, 
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without HeLa lysates and inhibitor. After background correction, the signal of reaction with 
inhibitor was divided with signal of reaction without inhibitor and multiplied by 100 to give 
percent remaining deacetylase activity at each concentration. The IC50 values were determined 
by fitting the percent deacetylase activity date against the concentration of small molecules in a 
sigmoidal dose-response curve (y=100/(1+(x/m1)
m2
)) using Kaleidograph 4.0 (Synergy) 
software, where m1 is the IC50 value in molar units.   
 
3.5.5 HeLa cell lysis 
 Refer to Chapter 2, Section 2.5.4  
3.5.6 ELISA-based HDAC activity assay 
 Refer to Chapter 2, Section 2.5.7 and 2.5.8 
3.5.7 Small Molecule Inhibitor Screening 
 Refer to Chapter 2, Section 2.5.9 
3.5.8 Quantitative analysis 
 Refer to Chapter 2, Section 2.5.10 
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APPENDIX A  
Figure A.1: HPLC injection of Crude R110-Lys(Ac) peptide, 3  
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Figure A.2: Reinjection of Rh110-Lys(Ac) substrate, 3 
 
 
Table A.1: Mean signal to background ratio of HDAC1 isoform with Rh110-Lys(Ac) HDAC 
substrate, 3 
Trials  Background (B) Signal (S) S/B ratio 
I 1189 4351 3.7 
II 1586 5292 3.3 
III 1298 4166 3.2 
IV 1392 4527 3.3 
Mean 1366 4684 3.1 
S.E   0.3 
S.D 168 494  
 
Individual HDAC1 was immunoprecipitated on to a secondary antibody coated 96 well plate 
followed by incubation with HeLa lysates. The deacetylase activity of the immunoprecipitated 
HDAC1 isoforms was monitored by Rh110-Lys(Ac) HDAC substrate 3 as described in Section 
2.2.2, Figure 2.4. The mean of background, (negative control signal with HeLa lysates, HDAC 
Fluor-De-Lys
TM
 buffer, Rh110-Lys(Ac) substrate 3, but no primary HDAC1 antibody) signal, 
(positive control with primary HDAC1 antibody, HeLa lysates, HDAC Fluor-De-Lys
TM
 buffer, 
Rh110-Lys(Ac) substrate 3), and signal to background (S/B) ratio of HDAC1 with standard 
errors (S.E) and standard deviation (S.D) are shown. 
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Table A.2: Calculations of Z' factor and % CV for HDAC1 
S.D of Signal (σs) 494 
S.D of Background (σ ) 168 
3*(σs+σ ) 1986 
Mean of Signal (µs) 4684 
Mean of Background (µb) 1366 
µs-µb 3218 
Z' factor 0.38 
CV 0.15 
% CV 16 
 
           
 (       )
|       |
 
Z' factor and percent coefficient of variation for HDAC1 activity assay using Rh110-Lys(Ac) 
substrate 3 (Chapter 2, Section 2.2.2, Figure 2.4, Table A.1) were calculated as described in 
Chapter 2, Section 2.4.11.  
 
 
Table A.3: Means signal to background ratio of HDAC2 isoform with Rh110-Lys(Ac) HDAC 
substrate, 3 
Trials Background (B) Signal (S) S/B ratio 
I 1504 8731 5.8 
II 1372 7914 5.8 
III 1298 8968 6.9 
IV 1238 7721 6.2 
Mean 1353 8334 6.2 
S.E   0.3 
S.D 115 609  
 
Individual HDAC2 was immunoprecipitated on to a secondary antibody coated 96 well plate 
followed by incubation with HeLa lysates. The deacetylase activity of the immunoprecipitated 
HDAC1 isoforms was monitored by Rh110-Lys(Ac) HDAC substrate 3 as described in Section 
2.2.2, Figure 2.4. The mean of background, (negative control signal with HeLa lysates, HDAC 
Fluor-De-Lys
TM
 buffer, Rh110-Lys(Ac) substrate 3, but no primary HDAC2 antibody) signal, 
(positive control with primary HDAC2 antibody, HeLa lysates, HDAC Fluor-De-Lys
TM
 buffer, 
Rh110-Lys(Ac) substrate 3), and signal to background (S/B) ratio of HDAC2 with standard 
errors (S.E) and standard deviation (S.D) are shown. 
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Table A.4: Signal to background ratio of HDAC substrates against whole HeLa cell lysates 
HDAC Substrate Trial I Trial II Trial III Mean S.E 
HDAC Biomol 14 11  13 1 
Rh110 Substrate 43 47  45 2 
HDAC Glo 143 125 179 149 16 
 
HDAC substrate was incubated with whole HeLa lysates individually and the deacetylase 
activity was monitored as described in Section 2.3.3 and Figure 2.6. Mean of signal (deacetylase 
activity with the HeLa lysates) to background (deacetylase activity in the absence of HeLa 
lysates) ratio of a minimum two independent trials with standard error (S.E) are shown. 
 
 
 
Table A.5: Mean of signal to background ratio of human HDAC1 affixed to the secondary 
antibody coated wells 
Trials Background Signal S/B ratio 
I 195 4250 22 
II 227 4388 19 
III 188 5045 27 
Mean 203 4561 23 
S.E   2.2 
S.D 21 425  
Individual human HDAC1 was immunoprecipitated from HeLa lysates on secondary antibody 
coated plates and the catalytic activity was determined using HDAC Glo
TM
 substrate as 
described in Section 2.2.3.1 and Figure 2.9. Mean of signal (reaction with primary HDAC1 
antibody, HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent), background 
(reaction with HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent, but without 
primary HDAC1 antibody), and signal to background (S/B) ratio of three independent trials with 
standard error (S.E) and standard deviation (S.D) are shown. 
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Table A.6: Mean of signal to background ratio of human HDAC2 affixed to the secondary 
antibody coated wells 
Trials Background Signal S/B ratio 
I 283 9584 34 
II 297 10669 36 
III 270 8803 33 
Mean 283 9685 34 
S.E   1.0 
S.D 14 937  
Individual human HDAC2 was immunoprecipitated from HeLa lysates on secondary antibody 
coated plates and the catalytic activity was determined using HDAC Glo
TM
 substrate as 
described in Section 2.2.3.1 and Figure 2.9. Mean of signal (reaction with primary HDAC2 
antibody, HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent), background 
(reaction with HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent, but without 
primary HDAC2 antibody), and signal to background (S/B) ratio of three independent trials with 
standard error (S.E) and standard deviation (S.D) are shown. 
 
Table A.7: Mean of signal to background ratio of human HDAC3 affixed to the secondary 
antibody coated wells 
Trials Background Signal S/B ratio 
I 186 835 4.5 
II 209 828 4.0 
III 207 938 4.5 
Mean 283 867 4.3 
S.E   0.2 
S.D 13 62  
Individual human HDAC3 was immunoprecipitated from HeLa lysates on secondary antibody 
coated plates and the catalytic activity was determined using HDAC Glo
TM
 substrate as 
described in Section 2.2.3.1 and Figure 2.9. Mean of signal (reaction with primary HDAC3 
antibody, HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent), background 
(reaction with HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent, but without 
primary HDAC3 antibody), and signal to background (S/B) ratio of three independent trials with 
standard error (S.E) and standard deviation (S.D) are shown. 
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Table A.8: Mean of signal to background ratio of human HDAC6 affixed to the secondary 
antibody coated wells  
Trials Background Signal S/B ratio 
I 217 1366 6.3 
II 185 1244 6.7 
III 156 1315 8.5 
Mean   7.1 
S.E   0.7 
S.D 31 61  
 
Individual human HDAC6 was immunoprecipitated from HeLa lysates on secondary antibody 
coated plates and the catalytic activity was determined using HDAC Glo
TM
 substrate as 
described in Section 2.2.3.1 and Figure 2.9. Mean of signal (reaction with primary HDAC6 
antibody, HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent), background 
(reaction with HeLa lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent, but without 
primary HDAC6 antibody), and signal to background (S/B) ratio of three independent trials with 
standard error (S.E) and standard deviation (S.D) are shown. 
 
Table A.9: Mean of signal to background ratio of human HDAC1 affixed to the high binding 
polystyrene plates  
Trials Background Signal S/B ratio 
I 182 3960 22 
II 160 4246 27 
III 161 4328 27 
IV 145 5096 35 
Mean 162 4408 28 
S.E   5.5 
S.D 15 485  
 
Individual human HDAC1 was affixed from HeLa lysates on high binding polystyrene plates and 
the catalytic activity was determined using HDAC Glo
TM
 substrate as described in Section 
2.2.3.2 and Figure 2.11. Mean of signal (reaction with primary HDAC1 antibody, HeLa lysates, 
HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent), background (reaction with HeLa lysates, 
HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent, but without primary HDAC1 antibody), and 
signal to background (S/B) ratio of three independent trials with standard error (S.E) and 
standard deviation (S.D) are shown. 
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Table A.10: Mean of signal to background ratio of human HDAC2 affixed to the wells of an 
high binding polystyrene plates  
Trials Background Signal S/B ratio 
I 173 17738 103 
II 219 19433 89 
III 195 16394 84 
Mean 196 17855 92 
S.E   9.9 
S.D 23 1523  
 
Individual human HDAC1, 2, and 6 were affixed from HeLa lysates on high binding polystyrene 
plates and the catalytic activity was determined using HDAC Glo
TM
 substrate as described in 
Section 2.2.3.2 and Figure 2.11. Mean of signal (reaction with primary HDAC2 antibody, HeLa 
lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent), background (reaction with HeLa 
lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent, but without primary HDAC2 
antibody), and signal to background (S/B) ratio of three independent trials with standard error 
(S.E) and standard deviation (S.D) are shown. 
 
 
Table A.11: Mean of signal to background ratio of human HDAC6 affixed to the wells of high 
binding polystyrene 96-well plates 
Trials Background Signal S/B ratio 
I 472 4298 9.1 
II 484 4284 8.9 
III 572 4967 8.7 
IV 653 4532 6.9 
Mean 545 4520 8.4 
S.E   0.5 
S.D 85 319  
 
Individual human HDAC1, 2, and 6 were affixed from HeLa lysates on high binding polystyrene 
plates and the catalytic activity was determined using HDAC Glo
TM
 substrate as described in 
Section 2.2.3.2 and Figure 2.11. Mean of signal (reaction with primary HDAC6 antibody, HeLa 
lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent), background (reaction with HeLa 
lysates, HDAC Glo
TM
 assay buffer, HDAC Glo
TM
 reagent, but without primary HDAC6 
antibody), and signal to background (S/B) ratio of three independent trials with standard error 
(S.E) and standard deviation (S.D) are shown. 
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Table A.12: Mean percent deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 isoforms in the presence of 1µM SAHA, Apicidin, or Tubastatin 
 
Individual human HDAC1, 2, 3, and 6 were immunoprecipitated from HeLa lysates on high-
binding polystyrene or secondary antibody coated 96-well plates and the catalytic activity was 
determined using HDAC Glo
TM
 substrate. Percent deacetylase activity was calculated by 
dividing the signal of reaction containing primary HDAC antibody, HeLa lysates, HDAC Glo
TM
 
reagent with inhibitor to the signal of reaction containing primary HDAC antibody, HeLa 
lysates, HDAC Glo
TM
 reagent without inhibitor and multiplying by 100 as described in Chapter 
2, Section 2.2.3.3, and Figure 2.12. Mean percent of signal to background of minimum three 
independent trials with standard error (S.E) is shown. 
 
Table A.13: Percentage remaining HDAC1 deacetylase activity after incubation with the 
individual concentrations of SAHA 
 
Concentration (M) Trial I Trial II Trial III Trial IV Mean S.E 
2.50E-07 8.7 6.5 14 9.9 9.8 2.0 
1.25E-07 19 12 27 18 19 3.0 
6.25E-08 29 19 44 31 31 5.0 
3.13E-08 49 38 64 51 51 5.0 
1.56E-08 74 57 80 64 69 5.0 
7.88e-09 105 74 91 81 88 7.0 
 
Deacetylase activity of affixed HDAC1 on secondary antibody coated plates in the presence of 
individual concentrations of SAHA was determined as described in Chapter 2, Section 2.2.3.3, 
and Figure 2.13. The percentage remaining HDAC1 deacetylase activity of individual 
independent trial, mean percentage HDAC1 deacetylase activity and standard error (S.E) are 
shown. 
 
 
HDACi Percent deacetylase activity 
 HDAC1 HDAC2 HDAC3 HDAC6 
SAHA 8.9±0.1 8.3±0.2 14±3.0 7.9±2.0 
Apicidin 3.6±0.3 2.1±0.2 31±5 81±0.1 
Tubastatin 60±7 81±4.0 81±4.7 14±6.0 
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Table A.14: Percentage remaining HDAC2 deacetylase activity after incubation with the 
individual concentrations of SAHA 
Concentration (M) Trial I Trial II Trial III Mean S.E 
5.00E-07 12 11 16 13 2.0 
2.50E-07 24 30 38 30 4.0 
1.25E-07 31 34 37 34 2.0 
6.25E-08 59 66 74 66 4.0 
3.13E-08 76 79 83 79 2.0 
1.56E-08 88 86 92 89 2.0 
 
Deacetylase activity of affixed HDAC2 on secondary antibody coated plates in the presence of 
individual concentrations of SAHA was determined as described in Chapter 2, Section 2.2.3.3, 
and Figure 2.13. The percentage remaining HDAC2 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
 
Table A.15: Percentage remaining HDAC3 deacetylase activity after incubation with the 
individual concentrations of SAHA 
Concentration (M) Trial I Trial II Trial III Mean SE 
2.50E-07 12 3.0 3.0 6.0 3.0 
1.25E-07 15 15 8.0 12 2.0 
6.25E-08 22 25 17 22 2.0 
3.13E-08 38 39 33 37 2.0 
1.56E-08 55 62 53 57 3.0 
7.88E-09 79 73 69 74 3.0 
 
Deacetylase activity of affixed HDAC3 on secondary antibody coated plates in the presence of 
individual concentrations of SAHA was determined as described in Chapter 2, Section 2.2.3.3, 
and Figure 2.13. The percentage remaining HDAC3 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
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Table A.16: Percentage remaining HDAC6 deacetylase activity after incubation with the 
individual concentrations of SAHA 
Concentration (M) Trial I Trial II Trial III Mean SE 
2.00E-07 5.0 3.0  4.0 1.0 
1.00E-07 31 32 10 24 7.0 
5.00E-08 46 43 26 39 6.0 
2.50E-08 45 64 60 56 6.0 
1.25E-08 78 77 80 79 1.0 
 
Deacetylase activity of affixed HDAC6 on secondary antibody coated plates in the presence of 
individual concentrations of SAHA was determined as described in Chapter 2, Section 2.2.3.3, 
and Figure 2.13. The percentage remaining HDAC6 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
 
Table A.17: Percentage remaining HDAC1 deacetylase activity after incubation with the 
individual concentrations of Apicidin 
Concentration (M) Trial I Trial II Trial III Mean SE 
4.00E-08 12 13 9.2 12 1.0 
2.00E-08 17 19 16 17 1.0 
1.00E-08 27 43 37 36 5.0 
5.00E-09 44 73 51 56 9.0 
2.50E-09 61 75 48 61 8.0 
1.25E-09 98 111 82 97 8.0 
 
Deacetylase activity of affixed HDAC1 on secondary antibody coated plates in the presence of 
individual concentrations of Apicidin was determined as described in Chapter 2, Section 2.2.3.3, 
and Figure 2.14. The percentage remaining HDAC1 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
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Table A.18: Percentage remaining HDAC2 deacetylase activity after incubation with the 
individual concentrations of Apicidin 
Concentration (M) Trial I Trial II Trial III Mean SE 
4.00E-08 12 11 17 14 2.0 
2.00E-08 24 22 28 24 2.0 
1.00E-08 34 32 42 36 3.0 
5.00E-09 50 46 52 49 2.0 
2.50E-09 64 63 73 66 3.0 
1.25E-09 83 78 82 81 2.0 
 
Deacetylase activity of affixed HDAC2 on secondary antibody coated plates in the presence of 
individual concentrations of Apicidin was determined as described in Chapter 2, Section 2.2.3.3, 
and Figure 2.14. The percentage remaining HDAC2 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
 
Table A.19: Percentage remaining HDAC3 deacetylase activity after incubation with the 
individual concentrations of Apicidin 
Concentration (M)  Trial I Trial II Trial III Mean SE 
2.00E-08 19  11 15 4.0 
1.00E-08 26 25 6.4 19 6.5 
5.00E-09 34 40 41 38 2.3 
2.50E-09 55 69 64 63 4.0 
1.25E-09 74 89 71 78 5.4 
 
Deacetylase activity of affixed HDAC3 on secondary antibody coated plates in the presence of 
individual concentrations of Apicidin was determined as described in Chapter 2, Section 2.2.3.3, 
and Figure 2.14. The percentage remaining HDAC3 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown 
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Table A.20: Percentage remaining HDAC1 deacetylase activity after incubation with the 
individual concentrations of Tubastatin 
Concentration (M) Trial I Trial II Trial III Mean SE 
2.00E-05 3.7  17 10 7.0 
1.00E-05 12 30 18 20 5.0 
5.00E-06 28 46 43 39 6.0 
2.50E-06 42 63 59 55 6.0 
1.25E-06 52 81 75 69 9.0 
6.25E-07 63 85 79 76 7.0 
 
Deacetylase activity of affixed HDAC1 on secondary antibody coated plates in the presence of 
individual concentrations of Tubastatin was determined as described in Chapter 2, Section 
2.2.3.3, and Figure 2.15. The percentage remaining HDAC1 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
 
 
Table A.21: Percentage remaining HDAC2 deacetylase activity after incubation with the 
individual concentrations of Tubastatin 
 
Concentration (M) Trial I Trial II Trial III Mean SE 
4.00E-05 4.1 6.4 6.4 5.6 1.0 
2.00E-05 19 19 12 17 2.0 
1.00E-05 3.4 25 26 18 7.0 
5.00E-06 51 46 40 45 3.0 
2.50E-06 75 60 62 66 5.0 
1.25E-06  74 78 76 2.0 
 
Deacetylase activity of affixed HDAC2 on secondary antibody coated plates in the presence of 
individual concentrations of Tubastatin was determined as described in Chapter 2, Section 
2.2.3.3, and Figure 2.15. The percentage remaining HDAC2 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
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Table A.22: Percentage remaining HDAC3 deacetylase activity after incubation with the 
individual concentrations of Tubastatin 
Concentration (M) Trial I Trial II Trial III Mean SE 
1.00E-05 14 31 32 26 6.0 
5.00E-06 30 37 37 35 2.0 
2.50E-06 41 45 45 44 1.0 
1.25E-06 58 81 78 72 7.0 
6.25E-07 99  94 96 3.0 
 
Deacetylase activity of affixed HDAC3 on secondary antibody coated plates in the presence of 
individual concentrations of Tubastatin was determined as described in Chapter 2, Section 
2.2.3.3, and Figure 2.15. The percentage remaining HDAC3 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown 
 
 
Table A.23: Percentage remaining HDAC6 deacetylase activity after incubation with the 
individual concentrations of Tubastatin 
Concentration (M) Trial I Trial II Trial III Trial IV Mean SE 
1.00E-07 28 22 32 16 24 4.0 
5.00E-08 44 24 45 33 37 5.0 
2.50E-08 57 51 36 65 52 6.0 
1.25E-08 94 70 53 69 72 8.0 
6.25E-09 120  76 92 96 13 
 
Deacetylase activity of affixed HDAC6 on secondary antibody coated plates in the presence of 
individual concentration of Tubastatin was determined as described in Chapter 2, Section 2.2.3.3 
and Figure 2.15. The percentage remaining HDAC6 deacetylase activity of individual 
independent trial, mean percentage deacetylase activity and standard error (S.E) are shown. 
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APPENDIX B  
 
Figure B.1: Dose response curve of C7-4-biphenylmethyl SAHA 8d with HeLa lysates. Whole 
HeLa lysates was incubated with individual concentrations of 8d. Deacetylase activity of HDAC 
enzymes was monitored using HDAC Fluor-De-Lys
TM
 assay kit (Enzo Life Sciences). Mean of 
percentage remaining deacetylase of minimum three independent trials was determined and fitted 
to a sigmoidal dose response curve to generate IC50 values associated with Chapter 3, Section 
3.1.1, and Table 3.2. 
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Table B.1: Percentage remaining HDAC deacetylase activity of HeLa lysates after incubation 
with C7-4-biphenylmethyl derivative, 8d 
Concentration (M) Trial 1 Trial II Trial III Trial IV 
2.5 x 10
-8
 36 17 13  
1.3 x 10
-8 
28 27 24 32 
6.2 x 10
-9 
37 38 38 42 
3.1 x 10
-9 
59 48 45 72 
1.6 x 10
-10 
74 62 69  
7.8 x 10
-10 
32 42 72 83 
 
Deacetylase activity of whole HeLa lysates was determined in the presence of individual 
concentration of C7-4-biphenylmethyl SAHA derivative using HDAC Fluor-De-Lys
TM
 activity 
assay kit from Enzo Life Sciences as described in Chapter 3, Section 3.1.1, Table 3.2, and Figure 
B.1. 
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Table B.2: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 with 100 nM C7-methyl SAHA derivative, 8a 
 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 21 42 64 31 
Trial 2 16 42 43 30 
Trial 3 40 30 42 23 
Trial 4 21 35 44 25 
Trial 5 28 33 42 28 
Trial 6 27 44 66 25 
Trial 7 14  57  
Trial 8 40  66  
Trial 9   57  
Trial 10   100  
Trial 11   110  
Mean 26 38 63 27 
S.E 3.0 2.0 7.0 1.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 8a with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 8a 
and multiplying by 100 as described in Section 3.1.3 and Figure 3.3. Mean and standard errors of 
independent trials are shown. 
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Table B.3: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 with 50 nM C7-benzyl SAHA derivative, 8b 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 57 54 61 62 
Trial 2 59 70 83 47 
Trial 3 70 73 81 49 
Trial 4 70 68 72 56 
Trial 5 64 68 64  
Trial 6   64  
Mean 64 67 71 54 
S. E 3.0 3.0 4.0 3.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 8b with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 8b 
and multiplying by 100 as described in Section 3.1.3 and Figure 3.3. Mean and standard errors of 
independent trials are shown. 
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Table B.4: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 with 20 nM C7-naphthyl SAHA derivative, 8c 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 87 71 90 66 
Trial 2 68 93 100 60 
Trial 3 85 84  58 
Trial 4 75 84  81 
Trial 5 76 81   
Mean 78 82 95 67 
S. E 13 9.0 4.0 3.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 8c with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 8c 
and multiplying by 100 as described in Section 3.1.3 and Figure 3.3. Mean and standard errors of 
independent trials are shown. 
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Table B.5: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 with 20 nM C7-4-biphenylmethyl SAHA derivative, 8d 
 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 46 43 69 48 
Trial 2 40 48 65 65 
Trial 3 39 45 101 73 
Trial 4 36 44 71 32 
Trial 5  47 89 58 
Trial 6   77  
Trial 7   57  
Trial 8   82  
Mean 40 45 77 54 
S. E 2.0 1.0 5.0 7.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 8d with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 8d 
and multiplying by 100 as described in Section 3.1.3 and Figure 3.3. Mean and standard errors of 
independent trials are shown. 
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Table B.6: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 with 20 nM C7-9-anthracenyl SAHA analog, 8e 
 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 19 68 94 67 
Trial 2 68 101 81 44 
Trial 3 78 70 87 59 
Trial 4 69 73 67 67 
Trial 5 76 74 81 21 
Trial 6 77 77 100 23 
Trial 7 70 80  23 
Trial 8 37 75  45 
Trial 9 81 49  47 
Trial 10 70 81   
Trial 11  104   
Mean 64 77 85 43 
S. E 6.0 5.0 5.0 6.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 8e with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 8e 
and multiplying by 100 as described in Section 3.1.3 and Figure 3.3. Mean and standard errors of 
independent trials are shown. 
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Table B.7: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 with 50 nM C7-9-tetrahydroanthracenylmethyl derivative, 8f 
 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 76 74 91 69 
Trial 2 84 106 82 37 
Trial 3 80 79 87 58 
Trial 4 74 84 87 72 
Trial 5 84 79 75 28 
Trial 6 67 84  35 
Trial 7 95 78  64 
Trial 8 101 49  45 
Trial 9  81  58 
Trial 10  104   
Mean 83 82 85 52 
S. E 4.0 5.0 3.0 5.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 8f with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 8f 
and multiplying by 100 as described in Section 3.1.3 and Figure 3.3. Mean and standard errors of 
independent trials are shown. 
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Table B.8: Percentage remaining HDAC1 deacetylase activity after incubation with C7-9-
anthracenylmethyl SAHA derivative, 8e 
Concentration (M) Trial I Trial II Trial III Trial IV Mean SE 
2.00E-07 28 24 21 29 26 2.0 
1.00E-07 42 31 4 39 29 8.0 
5.00E-08 62 52 46 54 54 3.0 
2.50E-08 67 58 85 72 71 6.0 
1.25E-08 85 77 87 81 83 2.0 
6.25E-09  98 80 80 86 6.0 
 
Deacetylase activity of mammalian HDAC1 immunoprecipitated on a high binding polystyrene 
plate in the presence of individual concentration of C7-9-anthracenylmethyl SAHA 8e derivative 
was determined as described in Chapter 3, Section 3.1.3, Table 3.3, and Figure 3.3.  
 
Table B.9: Percentage remaining HDAC2 deacetylase activity after incubation with C7-9-
anthracenylmethyl SAHA derivative, 8e 
Concentration (M) Trial I Trial II Trial III Mean SE 
2.00E-07 27 24 28 26 1.0 
1.00E-07 45 38 38 40 2.0 
5.00E-08 69 54 50 58 6.0 
2.50E-08 83 69 68 73 5.0 
1.25E-08  72 72 72 0 
6.25E-09  86 83 85 1.5 
 
Deacetylase activity of mammalian HDAC2 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of C7-9-anthracenylmethyl SAHA 
8e derivative was determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 
3.1.3, Table 3.3, and Figure 3.3. 
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Table B.10: Percentage remaining HDAC3 deacetylase activity after incubation with C7-9-
anthracenylmethyl SAHA derivative, 8e 
Concentration (M) Trial I Trial II Trial III Mean SE 
2.00E-07 30 16 23 23 4.0 
1.00E-07 45 67 64 59 7.0 
5.00E-08 88 105 87 93 6.0 
2.50E-08 72 119 87 93 14 
1.25E-08 68 124 101 98 16 
6.25E-09 123 133 115 124 5.0 
 
Deacetylase activity of mammalian HDAC3 immunoprecipitated on to a secondary antibody 
coated plate in the presence of individual concentration of C7-9-anthracenylmethyl SAHA 8e 
derivative was determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.1.3, 
Table 3.3, and Figure 3.3. 
.  
Table B.11: Percentage remaining HDAC6 deacetylase activity after incubation with C7-9-
anthracenylmethyl SAHA derivative, 8e 
Concentration (M) Trial I Trial II Trial III Mean SE 
5.00E-08 20 27 32 26 4.0 
2.50E-08 40 13 43 32 10 
1.25E-08 56 36 64 52 8.0 
6.25E-09  53 72 63 10 
3.13E-09   90 90 0 
1.56E-09   82 82 0 
 
Deacetylase activity of mammalian HDAC6 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of C7-9-anthracenylmethyl SAHA 
8e derivative was determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 
3.1.3, Table 3.3, and Figure 3.3. 
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Table B.12: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 isoforms after incubation with 5 µM of C2-methyl SAHA variant, 9a 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 82 64 99 33 
Trial 2 74 81 89 56 
Trial 3 49 74 106 30 
Trial 4 84 84 91 87 
Trial 5 22 83  61 
Trial 6 82 80  60 
Trial 7 46   67 
Trial 8 59   60 
Trial 9    39 
Mean 62 78 96 55 
S.E 8.0 4.0 4.0 7.0 
                                                                                                          
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9a with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9a 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Table B.13: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 isoforms after incubation with 5 µM of C2-ethyl SAHA derivative, 9b 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 96 66 88 70 
Trial 2 58 56 76 23 
Trial 3 80 74 101 42 
Trial 4 73 67 86 55 
Trial 5 67 82  65 
Trial 6 83 39  61 
Trial 7  22  61 
Trial 8  98  39 
Trial 9  60   
Trial 10  73   
Trial 11  73   
Mean 76 65 88 52 
S.E 5.0 6.0 5.0 6.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9b with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9b 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Table B.14: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 after incubation with 5 µM of C2-n-propyl analog SAHA, 9c 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 77 71 77 57 
Trial 2 71 69 70 26 
Trial 3 79 69 94 63 
Trial 4 57 70 103 48 
Trial 5 87 66  55 
Trial 6 82 67  56 
Trial 7    39 
Mean 75 69 86 49 
S.E 4.0 1.0 8.0 5.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9c with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9c 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Table B.15: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 after incubation with 10 µM of C2-n-butyl SAHA, 9d 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 42 89 83 38 
Trial 2 80 80 83 46 
Trial 3 65 76 86 51 
Trial 4 70  59 26 
Trial 5 88   35 
Mean 69 82 78 39 
S.E 2.0 4.0 4.0 1.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9d with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9d 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Table B.16: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 after incubation with 5 µM of C2-allyl SAHA derivative, 9e 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 110 82 87 35 
Trial 2 77 70 87 54 
Trial 3 86 81 100 20 
Trial 4 91 88 87 70 
Trial 5 74 76  56 
Trial 6 60 70  69 
Trial 7 82   72 
Trial 8    66 
Trial 9    27 
Mean 83 78 90 52 
S.E 7.0 2.0 3.0 7.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9e with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9e 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Table B.17: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 after incubation with 5 µM of C2-propargyl SAHA variant, 9f 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 95 92 108 30 
Trial 2 102 86 92 54 
Trial 3 101 97 98 44 
Trial 4 86 89 100 64 
Trial 5 63 89  83 
Trial 6  96  69 
Trial 7    89 
Trial 8    62 
Mean 90 91 99 62 
S.E 4.0 2.0 3.0 6.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9f with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9f 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Table B.18: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 after incubation with 5 µM of C2-benzyl SAHA, 9g 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 103 97 112 43 
Trial 2 99 100 100 30 
Trial 3 108 107 84 34 
Trial 4 107  87 47 
Trial 5   82  
Mean 104 102 96 36 
S.E 8.0 4.0 6.0 4.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9g with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9g 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Table B.19: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 after incubation with 5 µM of C2-n-pentyl SAHA, 9h 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 83 96 87 26 
Trial 2 80 86 89 26 
Trial 3 87 84 76 28 
Mean 84 89 84 27 
S.E 3.0 1.0 3.0 4.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9g with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9g 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
 
 
Table B.20: Percent remaining deacetylase activity of human HDAC1, HDAC2, HDAC3, and 
HDAC6 after incubation with 1µM of C2-n-hexyl SAHA, 9i 
 HDAC1 HDAC2 HDAC3 HDAC6 
Trial 1 84 87 89 25 
Trial 2 88 91 93 40 
Trial 3 93 88 83 34 
Mean 88 89 88 33 
S.E 6.0 3.0 3.0 7.0 
 
Percent remaining deacetylase activity was determined by dividing the luminescence signal of 
immunoprecipitated individual HDACs on the high binding polystyrene (HDAC1, HDAC2, and 
HDAC6) or secondary antibody coated plates (HDAC3) in the presence 9h with the 
luminescence signal of immunoprecipitated individual HDACs without the small molecule 9h 
and multiplying by 100 as described in Section 3.2.2 and Figure 3.6. Mean and standard errors of 
independent trials are shown. 
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Figure B.2: Dose dependent curves of C2-n-Pentyl SAHA analog 9h with individual human 
HDAC1, HDAC2, HDAC3, and HDAC6 isoforms. Mammalian individual HDAC isoforms are 
immunoprecipitated from HeLa cell lysates using HDAC activity assay and the catalytic activity 
of individual HDAC isoforms was tested in the absence and presence of varying concentrations 
of 9h. Error bars depict the standard error of more than three independent trials. In few cases, 
error bar is smaller than marker size. IC50 was determined by fitting data to a sigmoidal curve 
using Kaleidograph 4.0 (Synergy Software) associated with Chapter 3, Section 3.2.2, and Table 
3.5, Table B.21 to B.24. 
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Table B.21: Percentage remaining HDAC1 deacetylase activity after incubation with C2-n-
Pentyl SAHA analog, 9h 
Concentration Trial I Trial II Trial III Trial IV  Mean SE 
0.00032 10  9.2 7.8 13 9.9 1.0 
0.00016 12  21 15 17 16 2.0 
8.00E-05 27  36 33 33 32 2.0 
4.00E-05 47 57 55 56 56 54 2.0 
2.00E-05 61 72 72  69 69 3.0 
1.00E-05 76 84 73  81 78 3.0 
 
 Deacetylase activity of mammalian HDAC1 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of 9h derivative was determined 
using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.2.  
 
Table B.22: Percentage remaining HDAC2 deacetylase activity after incubation with C2-n-
Pentyl SAHA derivative, 9h 
Concentration Trial I Trial II Trial III Trial IV Mean SE 
0.00032  15 21 18 18 2.0 
0.00016  19 26 26 24 2.0 
8.00E-05  36 49 47 44 4.0 
4.00E-05 61 59 69 67 64 2.0 
2.00E-05 77 66 81 80 76 4.0 
1.00E-05 82 72 88 91 83 4.0 
 
Deacetylase activity of mammalian HDAC2 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of 9h derivative was determined 
using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.2. 
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Table B.23: Percentage remaining HDAC3 deacetylase activity after incubation with C2-n-
Pentyl SAHA, 9h derivative 
Concentration Trial I Trial II Trial III Trial IV Mean SE 
0.00016 26 0.9 15 16 14 5.9 
8.00E-05 26 9.6 30 26 23 5.0 
4.00E-05 48 33 47 45 43 4.0 
2.00E-05 72 55 66 57 63 4.0 
1.00E-05 76 71 78 81 76 2.0 
5.00E-06 99 83 102 87 93 5.0 
 
Deacetylase activity of mammalian HDAC3 immunoprecipitated on to a secondary antibody 
coated plate in the presence of individual concentration of 9h derivative was determined using 
HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.2. 
 
Table B.24: Percentage remaining HDAC6 deacetylase activity after incubation with C2-n-
Pentyl SAHA variant, 9h 
Concentration Trial I Trial II Trial III Trial IV Mean SE 
5.00E-06   0.5 16 8 8.0 
2.50E-06 28 22 13 15 19 4.0 
1.25E-06 39 58 43 35 44 5.0 
6.25E-07 52 61 68 56 59 4.0 
3.13E-07 73 102 120 96 98 10 
1.56E-07 94 76   85 9.0 
 
Deacetylase activity of mammalian HDAC6 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of 9h derivative was determined 
using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.2. 
 
 
 
 
132 
 
 
 
 
Figure B.3: Dose dependent curves of C2-n-Hexyl SAHA derivative 9i with individual 
human HDAC1, HDAC2, HDAC3, and HDAC6 isoforms. Mammalian individual HDAC 
isoforms are immunoprecipitated from HeLa cell lysates using HDAC activity assay and the 
catalytic activity of individual HDAC isoforms was tested in the absence and presence of varying 
concentrations of 9i. Error bars depict the standard error of more than three independent trials. In 
few cases, error bar is smaller than marker size. IC50 was determined by fitting data to a 
sigmoidal curve using Kaleidograph 4.0 (Synergy Software) associated with Chapter 3, Section 
3.2.2, and Table 3.5, Table B.25 to B.28 
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Table B.25: Percentage remaining HDAC1 deacetylase activity after incubation with C2-n-hexyl 
SAHA derivative, 9i 
Concentration Trial I Trial II Trial III Trial IV Mean SE 
0.00064  20 23 28 24 2.0 
0.00032 29 32 29 35 31 2.0 
0.00016 32 45 40 44 40 3.0 
8.00E-05 43 51 59 57 52 4.0 
4.00E-05  65 73 72 70 3.0 
2.00E-05 74 85 84 81 81 2.0 
  
Deacetylase activity of mammalian HDAC1 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of 9i derivative was determined 
using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.3. 
 
Table B.26: Percentage remaining HDAC2 deacetylase activity after incubation with C2-n-hexyl 
SAHA, 9i derivative 
Concentration Trial I Trial II Trial III Trial IV Mean SE 
0.00064  26 27 27 27 0.2 
0.00032 356 33 35 44 37 2.0 
0.00016 49 44 51  48 2.0 
8.00E-05 57 62 67 63 62 2.0 
4.00E-05 68 72 77 78 74 2.0 
2.00E-05 77 82 86 82 82 2.0 
 
 Deacetylase activity of mammalian HDAC2 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of 9i derivative was determined 
using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.3. 
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Table B.27: Percentage remaining HDAC3 deacetylase activity after incubation with C2-n-hexyl 
SAHA analog, 9i 
Concentration Trial I Trial II Trial III Mean SE 
0.00032 16 23 26 22 3.0 
0.00016 31 20 29 27 4.0 
8.00E-05 23 42 28 31 6.0 
4.00E-05 56 61 50 56 3.0 
2.00E-05 88 71 76 79 5.0 
1.00E-05 104 94 83 94 6.0 
 
 Deacetylase activity of mammalian HDAC3 immunoprecipitated on to a secondary antibody 
coated plate in the presence of individual concentration of 9i derivative was determined using 
HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.3. 
 
Table B.28: Percentage remaining HDAC6 deacetylase activity after incubation with C2-n-hexyl 
SAHA derivative, 9i 
Concentration Trial I Trial II Trial III Trial IV Trial V Mean SE 
5.00E-06 5.1   9.7 29 15 7.0 
2.50E-06 12 22 26 20 27 21 3.0 
1.25E-06 40 55 79 61 24 52 9.0 
6.25E-07 79 58 78 54 55 65 6.0 
3.13E-07 80 74 84 95 63 79 5.0 
  
Deacetylase activity of mammalian HDAC6 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of 9i derivative was determined 
using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure B.3. 
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Table B.29: Percentage remaining HDAC1 deacetylase activity after incubation with C2-benzyl 
SAHA derivative, 9g 
Concentration  Trial I Trial II Trial III Trial IV Mean SE 
0.0004 15 17 123  15 1.0 
0.0002 38 38 25 41 35 4.0 
1.00E-04 66 47 50 72 59 6.0 
5.00E-05 80 76  89 82 4.0 
2.50E-05 95 90  92 92 1.0 
1.25E-05 100 99 92 117 102 5.0 
 
Deacetylase activity of mammalian HDAC1 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of 9g derivative was determined 
using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and Figure 3.7. 
 
Table B.30: Percentage remaining HDAC2 deacetylase activity after incubation with C2-benzyl 
SAHA derivative, 9g 
Concentration  Trial I Trial II Trial III Trial IV Trial V Mean SE 
0.0004 22 22 17 16 24 20 2.0 
0.0002 49 48 35 42 43 43 3.0 
1.00E-04 70 80 60 62 61 67 4.0 
5.00E-05 84 61 64 83 76 74 5.0 
2.50E-05 96 103 82 84 84 90 4.0 
1.25E-05 94 103 93 98 92 96 2.0 
 
Deacetylase activity of mammalian HDAC2 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of C2-benzyl SAHA, 9g derivative 
was determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, 
and Figure 3.7. 
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Table B.31: Percentage remaining HDAC3 deacetylase activity after incubation with C2-benzyl 
SAHA derivative, 9g 
Concentration  Trial I Trial II Trial III Trial IV Mean SE 
0.0004 20 18 15  12 6.0 
0.0002 44 41 28 16 32 7.0 
1.00E-04 61 66 43 32 50 8.0 
5.00E-05 94 81 51 66 73 9.0 
2.50E-05 100 91 68 148 102 17 
1.25E-05 96 97 60 104 89 10 
 
Deacetylase activity of mammalian HDAC3 immunoprecipitated on to a secondary antibody 
coated plate in the presence of individual concentration of C2-benzyl SAHA, 9g derivative was 
determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, and 
Figure 3.7. 
 
 
 
Table B.32: Percentage remaining HDAC6 deacetylase activity after incubation with C2-benzyl 
SAHA derivative, 9g 
Concentration  Trial I Trial II Trial III Trial IV Trial V Mean SE 
4.00E-06  34 30 7.9 24 13 12 
2.00E-06  71 47 21 38 31 15 
1.00E-06 3.1 47 87 48 71 51 14 
5.00E-07 32 57 106 72 79 69 12 
2.50E-07 55 25 150 124 75 86 23 
1.25E-07  88 125 72 64 87 13 
 
Deacetylase activity of mammalian HDAC6 immunoprecipitated on to a high binding 
polystyrene plate in the presence of individual concentration of C2-benzyl SAHA, 9g derivative 
was determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.2.2, Table 3.5, 
and Figure 3.7. 
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Figure B.4: Dose dependent curves of C3-Ethyl SAHA derivative 10 with individual 
HDAC1, HDAC2, HDAC3, and HDAC6 isoforms. Mammalian individual HDAC isoforms are 
immunoprecipitated from HeLa cell lysates using HDAC activity assay on a secondary antibody 
coated plates and the catalytic activity of individual HDAC isoforms was tested in the absence 
and presence of varying concentrations of 10. Error bars depict the standard error of more than 
three independent trials. In few cases, error bar is smaller than marker size. IC50 was determined 
by fitting data to a sigmoidal curve using Kaleidograph 4.0 (Synergy Software) associated with 
Chapter 3, Section 3.3, and Table 3.7, B.33 to B.36. 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
10
-8
10
-7
10
-6
10
-5
0.0001 0.001
HDAC1
HDAC2
HDAC3
HDAC6
P
e
rc
e
n
t 
D
e
a
c
e
ty
la
s
e
 a
c
ti
v
it
y
C3-Ethyl SAHA (M)
y = 100/(1+(x/m3)^m4)
ErrorValue
7.3263e-79.6371e-6m3 
0.115911.2494m4 
NA67.641Chisq
NA0.99325R
y = 100/(1+(x/m3)^m4)
ErrorValue
7.1169e-71.2885e-5m3 
0.0803911.2051m4 
NA33.778Chisq
NA0.99623R
y = 100/(1+(x/m3)^m4)
ErrorValue
1.1606e-61.0045e-5m3 
0.221531.4305m4 
NA181.24Chisq
NA0.98599R
y = 100/(1+(x/m3)^m4)
ErrorValue
2.9275e-71.1486e-6m3 
0.322121.0984m4 
NA632.81Chisq
NA0.93503R
138 
 
 
 
Table B.33: Percentage remaining HDAC1 deacetylase activity after incubation with C3-Ethyl 
SAHA derivative, 10 
Concentration Trial I Trial II Trial III Mean SE 
5.00E-05 5.4 6.0 9.8 7.1 1.0 
2.50E-05 17 20 32 23 5.0 
1.25E-05 32 40 56 43 7.2 
6.25E-06 49 69 86 68 11 
3.13E-06 57 78 96 77 11 
1.56E-06  76 98 87 11 
 
Deacetylase activity of mammalian HDAC1 immunoprecipitated on secondary antibody coated 
plate in the presence of individual concentration of C3-Ethyl SAHA, 3 derivative was 
determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.3, Table 3.7, and 
Figure B.4.  
 
 
Table B.34: Percentage remaining HDAC2 deacetylase activity after incubation with C3-Ethyl 
SAHA derivative, 10 
Concentration Trial I Trial II Trial III Mean SE 
5.00E-05 8.4 14 21 14 4.0 
2.50E-05 21 29 40 30 6.0 
1.25E-05 38 57 63 52 8.0 
6.25E-06 67 77 76 73 3.0 
3.13E-06 71 92 86 83 6.0 
1.56E-06 79 98 89 89 5.0 
 
Deacetylase activity of mammalian HDAC2 immunoprecipitated on secondary antibody coated 
plate in the presence of individual concentration of compound 10 was determined using HDAC 
Glo
TM
 substrate as described in Chapter 3, Section 3.3, Table 3.7, and Figure B.4. 
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Table B.35: Percentage remaining HDAC3 deacetylase activity after incubation with C3-Ethyl 
SAHA analog, 10 
Concentration Trial I Trial II Trial III Mean SE 
5.00E-05 9.2 8.7 4.9 7.6 1.0 
2.50E-05 26 34 17 26 5.0 
1.25E-05 48 49 34 44 5.0 
6.25E-06 57 60 59 59 1.0 
3.13E-06 96 88 73 86 7.0 
1.56E-06 115 108 87 103 8.0 
 
Deacetylase activity of mammalian HDAC3 immunoprecipitated on to a secondary antibody 
coated plate in the presence of individual concentration of C3-Ethyl SAHA derivative, 10 was 
determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.3, Table 3.7, and 
Figure B.4. 
 
Table B.36: Percentage remaining HDAC6 deacetylase activity after incubation with C3-Ethyl 
SAHA variant, 10 
Concentration (M) Trial I Trial II Trial III Trial IV Trial V Trial VI Mean SE 
4.00E-06 36 8 42   17 26 8.0 
2.00E-06 40 16 65   34 39 10 
1.00E-06 39 41 45 54 46 42 45 2.0 
5.00E-07 73 46 90 103 63 59 72 8.0 
2.50E-07 67 69 82 68 73 96 76 5.0 
1.25E-07 123 131 98 99   113 8.0 
 
Deacetylase activity of mammalian HDAC6 immunoprecipitated on secondary antibody coated 
plate in the presence of individual concentration of C3-Ethyl SAHA derivative, 10 was 
determined using HDAC Glo
TM
 substrate as described in Chapter 3, Section 3.3, Table 3.7, and 
Figure B.4. 
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B.1: 6,6-dibenzyl 1-methyl 7-(biphenyl-4-yl)heptanes-1,6,6-tricarboxylate (6) 
B.1.1 
1
H NMR 
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B.1.2 
13
C NMR 
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B.1.3 LRMS 
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B.1.4 IR 
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B.2 : Methyl 7-(biphenyl-4-ylmethyl)-8-oxo-8-(phenylamino)octanoate (7d) 
B.2.1 
1
H NMR 
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13
C NMR 
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B.2.3 LRMS 
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B.2.4 IR  
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B.3: 2-(biphenyl-4-ylmethyl)-N
8
-hydroxy-N
1
-phenyloctanediamide (1d) 
B.3.1
1
H NMR 
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B.3.2 
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B.3.3 HRMS 
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B.3.4 IR  
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ABSTRACT 
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Major: Chemistry (Organic) 
Degree: Doctor of Philosophy 
 
Cancers are one of the leading causes of death in United States, effecting roughly 20% of the 
population. To develop effective anti-cancer agents, vast research is in progress that targets various 
factors leading to cancer. One such area of cancer research is developing drugs that inhibit histone 
deacetylase (HDAC) proteins. HDACs are histone modifying enzymes that regulate transcription of 
genes. Aberrant recruitment of HDACs to the transcription factors leads to tumor onset and growth. 
Because of their potential anti-cancer therapeutic interest, several HDAC inhibitors are in various 
stages of clinical trials. SAHA and Romidepsin are FDA-approved drugs for the treatment of 
cutaneous T-cell lymphoma. Human HDAC proteins have high sequence similarity and hence many 
known inhibitors non-specifically interact with all or most of the eleven HDAC isoforms, leading to 
possible side-effects. Hence, HDAC inhibitors specific to one HDAC isoforms (Isoform selective 
HDAC inhibitors) may overcome the potential clinical side effects and be effective anti-cancer drugs. 
In addition, isoform selective HDAC inhibitors would also be great tools to dissect the individual 
functions of HDAC isoforms in carcinogenesis. The most common assay to monitor the deacetylase 
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activity of HDAC, is the in vitro fluorescence assay that employs HDAC-Fluor-De-LysTM substrate. 
To screen small molecule for isoform selectivity using the assay, baclovirus expressed recombinant 
HDAC proteins are employed. However, inadequate, low throughput and expensive screening 
strategies using recombinant HDAC proteins have stalled the identification of isoform selective 
HDAC inhibitors. We report here the development of a high throughput ELISA-based HDAC 
activity assay to screen the inhibitors against human-derived HDAC isoforms for selectivity in a cost 
effective manner. A mini pilot screen was performed using the developed assay to determine the 
selectivity of the SAHA derivatives modified at the linker position with hydrophobic substituents, the 
C7-SAHA, C2-SAHA, and C3-Ethyl SAHA derivatives.  A HDAC6-selective inhibitor has been 
identified from the SAHA derivatives, which showed similar selectivity compared to the known 
HDAC6 selective tubastatin. The combined screening data of the SAHA derivatives suggest that 
modification at the linker region close to hydroxamic acid of SAHA with hydrophobic groups 
display some HDAC6 selectivity. However, SAHA derivatives modified at the region close to the 
capping group lead to more potent but less specific for compounds. Overall, the developed ELISA-
based HDAC activity assay show immense potential in the identification of selective HDAC 
inhibitors in cost-effective and high throughput manner using mammalian-cell derived proteins, 
which contribute to the greater field of anti-cancer drug development and HDAC-related cancer 
research. 
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